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ABSTRACT
Atherosclerosis and its ischemic symptoms are the leading causes of illness and deaths in Western
countries. Patients with cardiovascular diseases are increasingly older and have multiple other
comorbidities which limit the use of conventional treatments. Therapeutic gene transfer with
proangiogenic factors may offer new treatment opportunities for these patients.
In  this  study,  therapeutic  potency  of  vascular  endothelial  growth  factors  (VEGFs)  and  closely
related platelet derived growth factors (PDGFs) were studied. In the first study, we found that PDGF-C
was strongly expressed in the endothelium and lesion macrophages while PDGF-D expression was more
diffuse in the vessel wall in human atherosclerotic lesions. Next, therapeutic angiogenesis was studied in
rabbit hindlimb ischemia model and in mouse myocardium using adenoviral (Ad) gene delivery for
short-term and adeno-associated virus (AAV) for long-term gene expression, respectively. We observed
that the combination gene transfer of AdVEGF-A and AdPDGF-B enhanced the proliferation of pericytes
but that did not lead to the stabilization of newly formed blood vessels. However, the combination gene
transfer prolonged the angiogenic effect. Thirdly, AAV-VEGF-A was found to induce a 10-fold perfusion
increase compared to AAV-LacZ in rabbit hindlimb. Perfusion was followed for up to one year using a
high resolution ultrasound method. In comparison, AdVEGF-A gene transfer increased muscle perfusion
by 20-fold but that returned back to baseline in two weeks. As a side effect of long-term VEGF-A
expression, we observed remarkable histological disorganization of AAV-VEGF-A transduced skeletal
muscle. Finally, as a potential novel proangiogenic gene therapy, the effects of two hypoxia inducible
transcription factors (HIFs), HIF-1α and -2α, on angiogenesis and tissue energy metabolism were studied
in  ischemic  rabbit  hindlimb.  Gene  transfer  of  AdHIF-1α and AdHIF-2α were  found to  increase  skeletal
muscle perfusion by 4-fold compared to AdLacZ control. In addition, we observed that HIF gene transfer
enhanced the recovery of ischemic skeletal muscle from the energy loss induced by exercise evaluated
using magnetic resonance spectroscopy (MRS).
In  summary,  the  potential  of  vascular  growth  factors,  transcription  factors  and  different  viral
gene delivery vectors in proangiogenic gene therapy were studied. Enhancing angiogenesis together with
improved exercise tolerance by gene therapy is a promising new treatment strategy for the patients
suffering  from  impaired  vascular  function.  The  expression  time  and  intensity  can  be  controlled  by
choosing optimal therapeutic genes and viral vectors for a certain treatment application.
National Library of Medicine Classification: QU 107, QY 60.L3, QY 60.R6, QZ 52, WG 550, WN 185, WN 208
Medical Subject Headings: Atherosclerosis/therapy; Gene Therapy; Gene Transfer Techniques; Gene Expression;
Adenoviridae; Dependovirus; Blood Vessels; Disease Models, Animal; Rabbits; Mice; Endothelium, Vascular;
Hindlimb; Myocardium; Transcription Factors; Hypoxia-Inducible Factor 1; Ischemia; Platelet-Derived Growth
Factor/therapeutic  use;  Vascular  Endothelial  Growth  Factors/therapeutic  use;  Magnetic  Resonance  Spectroscopy;
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TIIVISTELMÄ
Valtimonkovettumatauti ja sen aiheuttamat verenkierron komplikaatiot, kuten alaraajaiskemia, ovat
suurin sairastavuuden ja kuolleisuuden aiheuttaja länsimaissa. Sydän- ja verisuonisairauksia sairastavat
potilaat ovat yhä vanhempia ja heillä on useita liitännäissairauksia, jotka rajoittavat perinteisten
hoitomuotojen käyttöä. Verisuonten uudismuodostus geeniterapian avulla voisi tarjota näille potilaille
uudenlaisen hoitomahdollisuuden.
Tässä tutkimuksessa selvitettiin verisuonen endoteelikasvutekijöiden (vascular endothelial
growth factor, VEGF) ja verihiutalekasvutekijöiden (platelet derived growth factor, PDGF) terapeuttisia
ominaisuuksia. PDGF-kasvutekijäperheeseen kuuluvien PDGF-C:n ja PDGF-D:n osoitettiin ilmentyvän
valtimonkovettumataudista kärsivissä ihmisen verisuonissa. PDGF-C ilmentyi voimakkaasti verisuonen
endoteelikerroksessa ja makrofaageissa. PDGF-D:n havaittiin ilmentyvän laajemmin suonen seinämässä.
Terapeuttista uudisverisuonten kasvua tutkittiin kanin alaraajamallissa sekä hiiren sydänlihaksessa.
Tutkimuksessa käytettiin lyhytaikaisen geeninilmentymisen aikaansaavaa adenovirusta (Ad) ja
pitkäaikaisen geenin-ilmentymisen aiheuttavaa adeno-assosioitua virusta (AAV). Havaitsimme AdVEGF-
A + AdPDGF-B yhdistelmägeeninsiirron lisäävän perisyyttejä kapillaarisuonten ympärillä, mutta
suotuisaa vaikutusta verisuonten pysyvyyteen verrattuna AdVEGF-A geeninsiirtoon ei saavutettu.
Yhdistelmägeeninsiirto kuitenkin sai aikaan pitkäkestoisemman verisuonten muodostuksen vasteen.
AAV-VEGF-A geeninsiirron osoitettiin pitävän verisuonten muodostus 10-kertaisena vuoden ajan
verrattuna kontrolligeeniin. AdVEGF-A lisäsi verisuonten muodostuksen 20-kertaiseksi vaikutuksen
kestäessä kaksi viikkoa. Pitkäaikaisen VEGF-A:n ilmentymisen havaittiin aiheuttavan lihaksessa
sivuvaikutuksena kudosmuutoksia. Tutkimme myös kudoksen hapenpuutteessa indusoituvien
transkriptiotekijöiden (hypoxia indicible factors, HIF) HIF-1α:n ja HIF-2α:n vaikutuksia uudisverisuonten
muodostukseen ja kudoksen energia-aineenvaihduntaan. AdHIF-1α:n ja AdHIF-2α geeninsiirtojen
havaittiin lisäävän luurankolihaksen verenkiertoa 4-kertaisesti kontrolligeeniin verrattuna. Työssä
osoitettiin ensimmäistä kertaa HIF geeninsiirron parantavan verenkierron puutteessa olevan lihaksen
energiavarastojen kykyä palautua rasituksesta.
Yhteenvetona voidaan todeta että kasvutekijöiden ja transkriptiotekijöiden geeninsiirrolla kahta
eri viruskuljetinta käyttäen saatiin kasvatettua uudisverisuonia ja parannettua merkittävästi
verenvirtauksen puutteessa olevan lihaksen rasituksen sietokykyä. Valitsemalla geeninsiirtovektori
halutun ilmentymisajan ja tehokkuuden perusteella voidaan jatkossa geeniterapiaa kohdentaa lihaksen
verenkierron ja hapenpuutteen hoitamiseksi.
Yleinen suomalainen asiasanasto: ateroskleroosi - - hoitomenetelmät; geeniterapia; geenitekniikka; adenovirukset;
iskemia; eläinkokeet; jänikset; hiiret; kasvutekijät; verisuonet; magneettitutkimus; spektroskopia; ultraäänitutkimus
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11 Introduction
Despite improved prevention and treatment of cardiovascular diseases, they are still the leading
cause of morbidity and mortality in Western countries. Atherosclerosis is an arterial disease
where lipid accumulation leads to inflammation and narrowing of the lumen of the blood vessel
(Lusis, 2000). In peripheral arterial disease (PAD), occluded arteries cannot provide sufficient
blood  flow  to  the  extremities  resulting  in  ischemia  (Kumar  et  al.,  2004).  Reduced  blood  flow
impairs the oxygen supply and decreases aerobic energy metabolism in the ischemic tissue. At
the same time, metabolites and waste products accumulate, which triggers inflammation and
causes malfunction of the tissue. At present, bypass surgery and percutaneous procedures
treatments are available for revascularization of the ischemic tissue. However, since many of the
patients suffering PAD are old, conventional treatment strategies become more challenging due
to the presence of diffuse and disseminated arterial disease, poor general health status or other
medical limitations in these patients. Gene transfer of growth factors is one emerging option for
the revascularization of ischemic limbs. In cardiovascular gene therapy, collateral blood vessels
are opened and new vessels grown after the administration of proangiogenic growth factors
(Yla-Herttuala and Alitalo, 2003). Two processes are needed to rescue ischemic tissue from
irreversible tissue necrosis: angiogenesis and arteriogenesis. Angiogenesis is a process where
new vessels are grown from pre-existing vessels via different mechanisms (Risau, 1997).
Arteriogenesis is the remodeling of conduit vessels by making them increase their diameter,
leading to increased blood flow (Schaper and Scholz, 2003). Many factors, including vascular
endothelial growth factors (VEGFs), platelet derived growth factors (PDGFs) as well as hypoxia
inducible transcription factors (HIFs) are involved in these processes. VEGF has been widely
used to induce angiogenesis in pre-clinical and clinical cardiovascular gene therapy studies
(Rissanen and Yla-Herttuala, 2007). In addition to increased angiogenesis, improvement in
tissue energy metabolism is needed to support proper tissue recovery from ischemia. The aim of
this thesis was to increase knowledge about the factors involved in atherosclerosis and to search
for new approaches to induce blood vessel growth in ischemic limbs. In this thesis, the
expression of PDGFs in human atherosclerotic lesions was characterized, and the angiogenic
power of VEGF-A, PDGFs and HIFs was evaluated in animal models using short- and long-
term gene expression.
2
32 Review of the literature
2.1 VASCULAR SYSTEM AND MECHANISMS OF VASCULAR GROWTH
2.1.1 Vascular system
The vascular system is the first organ to develop during fetal growth (Risau and Flamme, 1995).
The correct structure and function of blood vessels are essential for the developing organism.
Blood vessels supply oxygen and nutrients to the tissues, carry metabolites and waste products
for secretion and are essential for immune defense. The cardiovascular system consists of the
heart  as  a  pumping  regulator  of  blood  flow,  the  arteries  and  veins  transferring  blood  to  the
periphery and back to the heart, and the capillaries which are responsible for substance
exchange in tissues (Guyton and Hall, 2006). In general terms, blood vessels are formed in the
early state of ontogenesis, but also some blood vessel formation can occur in adults. Many
factors are involved in the correct formation of the blood vessels and the regulation of their
function. The rate of blood flow in tissues is controlled by many factors, such as the need for
oxygen and nutrients (Guyton and Hall, 2006).
2.1.2 Organization of vascular system
There are three types of blood vessels, arteries, capillaries and veins and these can be
differentiated by their size, structure and function. The vessel walls are composed of endothelial
cells (ECs), mural cells, and connective tissue. (Figure 1) Thick walled arteries carry oxygenated
blood from the heart to the periphery under high pressure, in normal conditions 80-120 mmHg
(Guyton and Hall, 2006). The diameters of human arteries vary from centimeters to millimeters.
The average of blood velocity in arteries is 33 cm/s. Arteries branch to smaller arteries and then
to even smaller branches before becoming capillaries which are called arterioles. Arterioles
control  the  flow  of  blood  into  capillaries  (Guyton  and  Hall,  2006).  Arterioles  have  a  strong
smooth  muscle  cell  (SMC)  layer  and  they  are  able  to  constrict  and  reduce,  even  close  the
vascular lumen or relax and dilate it, thus having a capability to respond quickly to the need of
tissues (Guyton and Hall, 2006).
4Capillaries, which are 4 to 9 µm in diameter, are connected to arteries and veins but their main
function is to supply oxygen and nutrients into tissues and carry carbon dioxide and waste
products  away  from  the  tissue.  The  capillary  length  may  be  only  0.3  to  1  millimeter  and  the
velocity of blood flow is typically 0.3mm/s. Capillaries have a very thin endothelial layer
enabling rapid substance exchange between the blood and the interstitial fluid (Guyton and
Hall, 2006). Capillary ECs are connected to each other by intercellular junctions. Several
biological factors can modulate endothelial junctions, such as inflammatory mediators and
growth factors, and in that way influence permeability across the endothelium (Toborek and
Kaiser, 1999).
Venules, 10 to 50 µm in diameter, collect blood from capillaries. One fourth of oxygen from red
blood cells is released in capillaries to tissue and carbon dioxide as a waste product from tissue
metabolism is collected for transportation. Venules become fused to form larger veins, with
diameters ranging from millimeters up to centimeters in humans. Veins carry oxygen-deprived
blood  back  to  the  heart  at  varying  velocities  and  low  pressure,  in  the  end  of  vena  cava  the
pressure is close to 0 mmHg (Guyton and Hall, 2006). Veins have the largest cross-sectional area
in the cardiovascular system and they are capable of constricting and enlarging. Thus, veins
provide a reservoir function for storing large quantities of extra blood, which can be taken into
use whenever needed elsewhere in circulation (Guyton and Hall, 2006).
Figure 1. Histological structure of an artery wall, a capillary and a vein wall (hematoxylin-eosin staining
from rabbit skeletal muscle). EC = endothelial cell, SMC = smooth muscle cell.
52.1.3 Vasculogenesis
The formation of blood vessels de novo during embryogenesis is called vasculogenesis (Figure 2)
(Risau  and  Flamme,  1995).  In  the  early  state  of  embryogenesis,  EC  progenitors,  mesodermal
angioblasts, differentiate to vascular plexuses, which will later develop into blood vessels. Some
angioblasts migrate to form vascular plexuses at distant sites.  Members of fibroblast growth
factor family are crucial in inducing the mesoderm to form angioblasts and hematopoietic cells
(Shalaby  et  al.,  1995a).  VEGF  is  essential  for  the  differentiation  of  ECs  and  the  further
development of the vascular system (Risau and Flamme, 1995; Carmeliet et al., 1996). Until
recently, it was thought that vasculogenesis was restricted to the perinatal period. The process
of differentiation of adult stem or progenitor cells and the de novo formation of blood vessels is
called postnatal vasculogenesis (Kassmeyer et al., 2009). Endothelial progenitor cells (EPCs)
have been shown to be mobilized endogenously by ischemia or exogenously by GM-CSF
stimulus, and improve neovascularization of ischemic tissues (Takahashi et al., 1999). In
addition, VEGF mobilizes bone marrow derived EPCs and contributes to neovascularization
(Asahara et al., 1999; Kalka et al., 2000). However, the effects on vascular growth rather seem to
be due to the increased levels of secreted growth factors of mobilized EPCs than to their direct
incorporation into the endothelium of neovessels (Rehman et al., 2003; Purhonen et al., 2008).
Additionally, hematopoietic stem cells isolated from umbilical cord vein have been shown to be
able to enhance the regenerative capacity of skeletal muscle after acute ischemic injury but even
though they do not directly participate in angiogenesis (Koponen et al., 2007).
2.1.4 Angiogenesis
Angiogenesis is vascular growth from pre-existing capillaries, which occurs by enlarging,
sprouting, bridging and non-sprouting angiogenesis called intussusceptions (Figure 2) (Risau,
1997; Conway et al., 2001). Angiogenesis is a common mechanism in tissue regeneration, e.g.
occuring in the menstrual cycle and wound healing, but it is present also in pathological
conditions like diabetic retinopathy and tumor growth (Risau, 1997).  Hypoxia is the principal
physiological stimulator for angiogenesis, and a low oxygen level activates HIF which in turn
up-regulates other pro-angiogenic factors such as VEGF (Fong, 2008). The first step in
angiogenesis is the vasodilatation of capillaries followed by increases in permeability and
degradation of the extracellular matrix, which leads to EC activation. Activated ECs proliferate
and  migrate  to  distant  sites  under  the  influence  of  many  factors  including  FGF,  VEGF  and
angiopoietins and their receptors (Conway et al., 2001). Migrated ECs clusters in the interstitial
6space, form lumen structures and finally fuse with existing vessels to create larger vessels
(Conway  et  al.,  2001).  The  Branching  of  newly  formed  vessels  can  result  from  several
mechanisms: new vessel branches can sprout towards ECs clusters in the surrounding
mesenchyme, vessels can split to form daughter vessels by bridging of ECs, or branching can
occur via intussusceptions where surrounding tissues invade the vessel lumen splitting the
vessel into two new vessels (Conway et al., 2001).  Newly formed vessels are often leaky
because of the loose EC junctions and this leakiness can cause protein extravasation which
increases the osmotic pressure in surrounding tissues leading to tissue edema (Guyton and
Hall, 2006). Tissue edema cannot be avoided during efficient angiogenesis, and in fact, a high
amount of extravasated protein correlates with the increase in capillary size (Rissanen et al.,
2003). In addition to EC function in angiogenesis, peri-endothelial mural cells and extracellular
matrix play important roles in the maturation of vessel wall (Jain, 2003). Nascent vessels recruit
SMCs, which stabilize newly formed vessels by inhibiting EC proliferation and migration
(Conway  et  al.,  2001).  PDGF  is  an  important  regulator  of  the  maturation  of  the  vessels  by
mediating SMC and pericyte differentiation, proliferation and migration (Lindahl et al., 1997;
Hellberg et al., 2010).
2.1.5 Arteriogenesis
Arteriogenesis refers to the transformation of small arterioles into much larger conducting
arteries (Figure 2) (Schaper and Scholz, 2003). Unlike angiogenesis, arteriogenesis is not induced
by hypoxia (Deindl et al., 2001). Arteriogenesis is induced by physiological forces and refers to
the remodeling of existing arterioles to increase their luminal diameter in response to increased
blood flow (Heil et al., 2006; Conway et al., 2001). Collateral growth by arteriogenesis occurs
next to an occluded artery, while angiogenesis takes place in an ischemic area distal from the
occlusion (Ito et al., 1997; Schaper and Scholz, 2003). Occlusion in the artery leads to a decrease
in blood pressure in the region distal from the occlusion and that in turn increases blood flow in
pre-existing small collateral arteries leading to more shear stress and elevated pressure on the
vessel wall.  Fluid shear stress is a strong mechanical inducer of arteriogenesis (Heil et al., 2006).
Shear stress activates the endothelium to express monocyte chemoattractant protein (MCP-1)
which together with transforming growth factor (TGF) attracts circulating monocytes to adhere
and penetrate into the intima. These adhering monocytes secrete growth factors and proteases
(Scholz et al., 2000).
7Figure 2. Mechanisms of vascular growth. Modified from Korpisalo and Ylä-Herttuala 2010
In the remodeling phase of arteriogenesis, SMCs start to proliferate, the vessel wall thickens and
the intima is formed. The collaterals grow in length. Their main characteristic is their tortuous
shape (Schaper and Scholz, 2003; Scholz et al.,  2000).  Some weeks after an occlusion only the
largest collaterals remain and maintain blood flow while small collaterals have regressed
ensuring the most efficient blood flow and low energy consumption (Hoefer et al., 2001).
2.2 VASCULAR GROWTH FACTORS
2.2.1 VEGFs and their receptors
Vascular endothelial growth factor A (VEGF-A or VEGF) was the first member of VEGF family
cloned in 1989 (Leung et al., 1989; Ferrara and Henzel, 1989). It is a crucial growth factor for
physiological and pathological angiogenesis. In adults, VEGF-A is expressed in all vascularized
tissues, especially in fenestrated and sinusoidal vessels in endocrine and secretory organs as
well as in blood vessels, skeletal muscle and myocardium, emphasizing its importance in
8vascular homeostasis(Maharaj et al., 2006). Embryos lacking only a single allele of vegf-a will die
in utero in E11 to E12 due to abnormalities in the vascular system (Carmeliet et al., 1996). VEGF-
A induces vasodilatation, and vascular permeability, maintains EC survival and stimulates EC
proliferation and migration (Ferrara et al., 2003). The expression of VEGF-A in the endothelium
is up-regulated during tissue injury as well as by inflammation, especially under hypoxia. It is
known that hypoxia can induce VEGF-A expression in tissues (Minchenko et al., 1994).
The human VEGF-A gene consists of eight exons separated by seven introns with isoforms
being produced by mRNA splicing. At least seven different VEGF-A isoforms are currently
known: VEGF-A121, VEGF-A145, VEGF-A162, VEGF-A165, VEGF-A183, VEGF-A189 and VEGF-A206
(Tischer et al., 1991; Poltorak et al., 1997; Jingjing et al., 1999; Lange et al., 2003). The most
widely studied isoform, VEGF-A165,  is  a  45  kDa glycoprotein that  binds to  heparin on the cell
surface and forms homodimers via cysteine bonding (Ferrara and Henzel, 1989). In addition,
VEGF-A189 and VEGF-A206 bind tightly to heparin and exist mainly bound to the extracellular
matrix. VEGF-A121 is a freely soluble isoform as it does not bind to heparin (Houck et al., 1992).
VEGF-A signaling is transduced via two receptor tyrosine kinase receptors, VEGFR-1 and
VEGFR-2 (de Vries et al., 1992; Terman et al., 1992). Both receptors have high affinity binding
sites for VEGF-A (Waltenberger et al., 1994).
VEGF-B growth factor is particularly highly expressed in the heart and skeletal muscle, and it
has about 43 % identical amino acid sequence with VEGF-A (Olofsson et al., 1996). VEGF-B has
two splice variants: heparin binding VEGF-B167 and freely soluble VEGF-B186. VEGF-B binds
selectively to VEGFR-1 (Olofsson et al., 1998). The expression of VEGF-B is not regulated by
hypoxia.  Since it  lacks  the hypoxia  responsive elements  in  the promoter  area,  and the mRNA
levels of VEGF-B are not changed by hypoxia (Enholm et al., 1997). VEGF-B has effects on the
myocardium. Vegf-b-/- mice have smaller hearts, vascular dysfunction and they recover poorly
from myocardial ischemia in comparison to normal mice (Bellomo et al., 2000). Another study
revealed that vegf-b-/- mice suffer an atrial conduction abnormality, but no changes in proper
development of the cardiovascular system either during development or as adults (Aase et al.,
2001). VEGF-B induces angiogenesis in the heart via VEGFR-1 and neuropilin-1 (Lahteenvuo et
al., 2009). VEGF-B has been reported to have species specific properties to influence the growth
coronary arteries (Bry et al., 2010).
VEGF-C and VEGF-D are similar in their structural and functional properties. VEGF-C was
cloned in  1996 and VEGF-D in 1997 (Orlandini  et  al.,  1996;  Yamada et  al.,  1997;  Joukov et  al.,
1996a). VEGF-C and –D are secreted as precursor proteins, which are proteolytically cleaved to
mature forms which possess VEGF homology domains (Joukov et al., 1997; Achen et al., 1998).
The mature forms of VEGF-C and VEGF-D bind predominantly to VEGFR-2 and the precursor
forms to VEGFR-3 (Li and Eriksson, 2001). VEGF-C is an essential factor for normal lymphatic
9development and during lymphangiogenesis in adults (Karkkainen et al., 2004). VEGF-C
mRNA is mainly expressed in lymph nodes, heart, placenta, ovaries, small intestine and thyroid
(Joukov et al., 1996b; Kukk et al., 1996). It has also been shown to increase vascular EC mitosis,
migration  and  permeability  and  have  an  angiogenic  effect  on  mouse  eye  (Cao  et  al.,  1998).
VEGF-D induces lymphangiogenesis via VEGFR-3 and its mRNA is mainly expressed in heart,
lungs and small intestine with smaller amounts in skeletal muscle, large intestine and pancreas
(Achen et al., 1998). Mature VEGF-D is also a powerfull vascular growth factor and it functions
via VEGFR-2 (Rissanen et al., 2003).
VEGF-E  is  a  VEGF-A  homologue,  which  was  found  in  the  Orf-virus  (Lyttle  et  al.,  1994).  It  is
similar to VEGF-A121 in its properties and is a non-heparin binding, freely soluble growth factor.
(Ogawa et al., 1998) VEGF-E binds to VEGFR-2 and induces EC proliferation, migration and
angiogenesis in vivo (Meyer et al., 1999). The angiogenic efficacy of VEGF-E is close to that of
VEGF-A but it causes fewer side effects than VEGF-A in transgenic mice (Kiba et al., 2003).
Placental growth factor (PlGF), which belongs to the VEGF superfamily, was identified from a
placental cDNA library (Maglione et al., 1991). PlGF has two protein variants: one is 149 amino
acids long PlGF-1 which is cleaved to form a functional soluble protein consisting of 129 amino
acids, and another the 170 amino acids containing heparin binding form PlGF-2 (Maglione et al.,
1993; Hauser and Weich, 1993). PlGF is mainly expressed in the placenta, thyroid gland and
lungs (Ziche et al., 1997). PlGF forms heterodimers with VEGF-A and its angiogenic properties
are partly explained by this feature (DiSalvo et al., 1995). PlGF binds specifically to VEGFR-1
(Clauss  et  al.,  1996).  It  has  also  been  observed  that  PlGF  binding  to  VEGFR-1  causes
transphosphorylation of VEGFR-2 and enhances VEGF-A mediated angiogenesis (Autiero et al.,
2003). PlGF also induces angiogenesis via upregulation of VEGF-A (Roy et al., 2005).
Furthermore,  it is known to evoke angiogenesis and arteriogenesis in skeletal muscle and heart
almost as effectively as VEGF-A (Luttun et al., 2002). Plgf-/- mice display defects in angiogenesis
and collateral vessel growth after tissue injury and this can be alleviated by a bone marrow
transplantation pointing to a role of PlGF in the mobilization of bone marrow-derived cells
(Carmeliet et al., 2001).
Signal transduction of the members of the VEGF family is mediated via five receptors (Figure
3).  VEGFR-1  or  fms-like  tyrosine  kinase  receptor  (Flt-1)  was  cloned  in  1989  and  further
characterized in 1992 (de Vries et al., 1992; Shibuya et al., 1989). VEGFR-1 plays an important
role in the organization of embryonic vasculature but is not necessary for the EC formation
(Fong et al., 1995). It also mediates PlGF induced capillary formation (Cai et al., 2003). In
addition to ECs, VEGFR-1 is expressed on monocytes where it mediates VEGF-A and PlGF
induced chemotaxis and downstream signaling (Barleon et al., 1996; Clauss et al., 1996;
Tchaikovski et al., 2008). VEGFR-1 is also expressed in SMCs where its phosphorylation
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activates metalloproteinases and induces SMC migration (Wang and Keiser, 1998). It has also
been postulated that VEGFR-1 does not directly mediate signal transduction but rather acts as a
decoy receptor for VEGFR-2 ligands (Ferrara et al., 2003). It has also been claimed that VEGFR-1
can decrease VEGFR-2 expression in vitro and modulate VEGF-A mediated vascular growth
(Rahimi et al., 2000). In addition, its soluble isoform, sVEGFR-1, inhibits VEGF-A activity
(Kendall  and  Thomas,  1993).  Recent  data  suggest  that  VEGFR-1  has  an  important  role  in  EC
adaptation in hypoxia. VEGFR-1:VEGFR-2 ratio is elevated under hypoxia leading to decreased
VEGF-A-mediated VEGFR-2 signaling in hypoxic ECs. This mechanism may release more
oxygen for viable cells which are able to renewal and repair tissue (Ulyatt et al., 2010).
Figure 3. VEGF family members and their binding to receptors. Modified from Ylä-Herttuala et. al. 2007.
VEGFR-2 or kinase domain region (KDR or Flk1) was cloned from human EC cDNA library in
1992  (Terman  et  al.,  1992).  It  is  the  major  mediator  of  the  mitogenic,  angiogenic  and
permeability-enhancing  effects  of  VEGF-A  (Ferrara  et  al.,  2003).  It  has  a  key  role  in
developmental vascular growth and hematopoiesis and therefore flk1-/- mice die in utero
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between days E8.5 and E9.5 due to the lack of vasculogenesis and the failure to develop blood
islands and organized blood vessels (Shalaby et al., 1995). VEGFR-2 mediates vascular EC
growth and migration in vitro and angiogenesis and vascular permeability in vivo (Waltenberger
et al., 1994; Gille et al., 2001).
VEGFR-3 or fms-like tyrosine kinase receptor-4 was cloned in 1992, and its expression has been
detected in many cancer cell lines, and in spleen, brain and lung in embryos but not in vascular
ECs (Pajusola et al., 1992). Subsequently, the expression of VEGFR-3 was found to be restricted
in the lymphatic endothelium during the development and to be increased in lymphatic
sinuses, metastatic lymph nodes and lymphangiomas (Kaipainen et al., 1995). VEGFR-3
mediates signal transduction involved in growth, migration and survival of lymphatic ECs and
it is critical for the lymphatic vessel growth and homeostasis. Thus, it is important in the
regulation of tissue edema (Veikkola et al., 2001; Makinen et al., 2001b; Makinen et al., 2001a).
Neuropilins are closely related to VEGF signaling. Neuropilin 1 (Nrp-1) binds to VEGF-A165,
PlGF-2, VEGF-B and VEGF-E (Klagsbrun et al., 2002). Overexpression of Nrp-1 in transgenic
mice leads to increased capillary formation and vasodilatation but can also cause cardiac
malformation (Kitsukawa et al., 1995). Mice lacking nrp-1 gene have problems in the formation
of neuronal axons and blood vessels (Kawasaki et al., 1999). Nrp-1 is a co-receptor for VEGFR-2
enhancing VEGF-A binding to VEGFR-2 and this leads to increased cell chemotaxis and growth
(Zachary, 2003). Nrp-1 is also an important regulator of VEGF-A induced tissue permeability
(Becker et al., 2005). Neuropilin-2 (Nrp-2) is known to be involved in lymphatic vessel function
(Yuan et al., 2002). For example, it has been reported that Nrp-2 binds to VEGF-C and VEGF-D
and forms complex with VEGFR-3 contributing to lymphatic functions (Karkkainen et al., 2001;
Karpanen et al., 2006).
2.2.2 PDGFs and their receptors
PDGFs belong to the PDGF/VEGF superfamily, of which there are four known members. PDGF-
B  (also  known  PDGF)  was  identified  in  the  1970s  (Kohler  and  Lipton,  1974;  Ross  et  al.,  1974;
Westermark and Wasteson, 1976) and PDGF-A in the mid 1980s (Antoniades et al., 1979;
Betsholtz et al., 1986). They are mitogens for mesenchymal cells including SMCs, bone and
cartilage cells (Heldin and Westermark, 1999). PDGF-A mRNA is highly expressed in most
human tissues with the highest expression being seen in the heart, pancreas and skeletal muscle
(Fredriksson et al., 2004). Deletion of the pdgf-a gene in mice leads to their death at three weeks
of age due to defects in alveoli formation (Bostrom et al., 1996). Pdgf-a knock-out mice display
multiple pathologies including the lack of SMCs in lungs and abnormalities in
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oligodendrocytes, skin, intestine and testis (Li and Eriksson, 2003). PDGF-B has 50 % identical
amino acid sequence to PDGF-A. PDGF-B mRNA is expressed in most human tissues with the
highest amounts found in the heart and the placenta (Fredriksson et al., 2004). Deletion of pdgf-b
gene causes defects in the development of kidneys and blood vessels, and bleeding at the time
of birth due to the inability of the newly formed vessels to attract pericytes (Leveen et al., 1994;
Lindahl et al., 1997). It has also been reported that PDGF-B affects angiogenesis mainly via SMC
and pericyte recruitment (Heldin and Westermark, 1999). PDGF-B is strongly present in the
atherosclerosis and has influence on inflammatory response during the atherosclerotic
processes (Bohm et al., 1994; Tang et al., 2005)
PDGF-C and PDGF-D were discovered more recently and their biological functions remain
somewhat unclear (LaRochelle et al., 2001; Bergsten et al., 2001; Li et al., 2000). In human tissues,
high PDGF-C mRNA expression levels have been observed in the heart, liver, kidney, pancreas
and ovaries, and lower levels in the placenta, skeletal muscle and prostate (Li et al., 2000).
PDGF-D mRNA expression is high in several human tissues e.g. the adrenal glands, heart,
pancreas and ovaries and low in some other tissues, such as adipose tissue, placenta and liver
(LaRochelle et al., 2001; Bergsten et al., 2001). Both PDGF-C and PDGF-D antigens are present in
renal arterial wall in SMC layer and in adventitial connective tissue (Uutela et al., 2001).
Differences in the expression occur in primary vascular cells as PDGF-C was highly expressed
in the coronary artery SMCs whereas PDGF-D expression was more pronounced in umbilical
vein and microvascular ECs (Uutela et al., 2001). Proangiogenic effects of PDGF-C have been
reported (Li et al., 2005). However, both PDGF-C and PDGF-D are more strongly linked to
tissue fibrosis and SMC proliferation. PDGF-C is a strong inducer of fibroblast proliferation,
and it causes cardiac hypertrophy and cardiomyopathy in transgenic mice (Ponten et al., 2003).
Similar to PDGF-C, PDGF-D is a strong chemoattractant and it recruits macrophages and
participates in vessel maturation during VEGFR-2 mediated angiogenesis in the mouse wound
healing model (Uutela et al., 2004). In addition, PDGF-D overexpression in the heart had caused
cardiac fibrosis and additionally proliferation of SMCs (Ponten et al., 2005).
PDGFs signal via two receptor tyrosine kinases PDGFR-α and PDGFR-β, and the PDGFR-αβ
heterodimer also exists. Ligand binding promotes receptor dimerization, which activates signal
transduction. PDGFR-α signaling is involved in gastrulation, the development of neural
structures, gonads, lung, intestine, skin, central nervous system (CNS) and the skeleton.
PDGFR-β signaling is important in blood vessel formation and early hematopoiesis (Andrae et
al., 2008). Figure 4 presents the PDGF family ligands and their binding to the receptors.
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2.2.3 HIFs
HIF-1α is a transcription factor mediating adaptive responses to low cellular oxygen levels
(Wang et al., 1995). Under normal cellular oxygen conditions, HIF-1α is continuously translated
but  rapidly  degraded  in  proteasomes.  In  the  degradation  process,  two  proline  residues,  P402
and 564 are hydroxylated by prolyl hydroxylases which leads to the binding of von Hippel-
Lindau protein and recruitment of E3 ubiquitin-protein ligase, resulting in HIF-1α
ubiquitination and proteasomal degradation (Jaakkola et al., 2001; Maxwell et al., 1999). Factor
inhibiting HIF (FIH) hydroxylates the asparagine residue 803 and this prevents the binding of
the transcriptional co-activator p300 (Mahon et al., 2001; Lando et al., 2002). During hypoxia, the
hydroxylase activity is inhibited and HIF-1α levels rapidly increase. HIF-1α translocates to the
nucleus and forms the HIF-1 heterodimer with constitutively expressed HIF-1β (Wang et al.,
1995a). HIF-1 binds to hypoxia responsible elements (HREs) in a gene promoter area (Semenza
et al., 1996). The Deletion of the hif-1α gene leads to embryonal death at day E11 due to neural
tube defects, cardiovascular malformations, and marked cell death within the cephalic
mesenchyme (Iyer et al., 1998). HIF-1α is the main factor governing tissue oxygen homeostasis
and it regulates the expression of many genes including genes involved in angiogenesis,
metabolism and erythropoiesis (Hirota and Semenza, 2006). VEGF-A is a central angiogenic
gene upregulated by HIF-1α (Forsythe et al., 1996). Puryvate dehydrogenase kinase 1 (PDK1) is
one of the metabolic target genes of HIF-1α. PDK1 is an important enzyme for attenuation of
Figure 4. Platelet derived growth factors and their receptors. Ligands with proved to be important
interactions in vivo are shown in black and other interactions (ligands in grey) have been demonstrat-
ed so far only in cell culture. Modified from Andrae et. al. 2008
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mitochondrial reactive oxygen species production, maintenance of ATP levels, and adaptation
to hypoxia (Kim et al., 2006; Papandreou et al., 2006).
HIF-2α or endothelial PAS Domain Protein-1 (EPAS-1) shares 48 % sequence identity with HIF-
1α (Tian et al., 1997). HIF-2α mRNA is present in many tissues and strongly expressed in the
heart, placenta and lung (Tian et al., 1997). The regulation of HIF-2α expression is similar to
HIF-1α and it is also induced by hypoxia (Wiesener et al., 1998).  In contrast to widely expressed
HIF-1α,  HIF-2α seems to be expressed only certain tissues (Wiesener et al.,  2003). In a similar
manner as HIF-1α, during hypoxia HIF-2α binds to HIF-1β and translocates to nucleus prior to
DNA binding and gene activation in hypoxia (Tian et al., 1997). HIF-2α knockout mice exhibit
multiple pathological and metabolic abnormalities including retinopathy, cardiac hypertrophy,
skeletal myopathy and mitochondrial abnormalities (Scortegagna et al., 2003). In addition, HIF-
2α is involved in regulating the expression of VEGF-A and VEGFR-1 (Takeda et al., 2004). Both
HIF-1α and HIF-2α bind to HRE in DNA sequences but they differ from transactivation domain
suggesting that they may have unique target genes (Loboda et al., 2010).
2.3 Cardiovascular diseases
2.3.1 Atherosclerosis
Atherosclerosis is a progressive disease characterized by the accumulation of lipids, SMCs and
fibrous elements in the arteries (Lusis, 2000; Libby, 2002). There are many risk factors for this
disease, e.g. elevated serum low density lipoprotein (LDL) levels, low serum high density
lipoprotein (HDL) levels, elevated blood pressure, obesity, high-fat diet, smoking and lack of
exercise for this common disease (Lusis, 2000). Atherosclerosis is initiated by the accumulation
of LDL in the subendothelial matrix, which acts to attract monocyte influx. Monocytes
differentiate into macrophages and take up lipoproteins (Lusis, 2000). The LDL is modified e.g.
oxidized, before the macrophages can take it up (Steinberg et al., 1989). The lipoprotein-rich
macrophages turn into foam cells and form the first lesion phase, fatty streaks, in the vessel wall
(Lusis, 2000).
The accumulation of oxidized LDL stimulates ECs to produce a number of pro-inflammatory
molecules and growth factors such as macrophage colony stimulating factor (M-CSF), and these
factors in turn recruit monocytes and lymphocytes. Cytokines and growth factors induce SMC
migration into the intima and promote their proliferation (Lusis, 2000). The intimal SMCs which
have  migrated  from  the  media  produce  extracellular  matrix  and  induce  the  formation  of
plaques, the second phase of the atherosclerotic lesion. With time, cells die and release their
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lipid contents  into the intima which gives  rise  to  the necrotic  core  of  the lesion (Lusis,  2000).
Initially, the atherosclerotic lesion grows towards the adventitia, but after a certain point, it
starts to expand inwards and obstructs the lumen.  In the same lesions, the plaques become
vulnerable especially if proteinases have degraded the fibrotic cap. In addition, the presence of
inflammation can enhance plaque destabilization. The calcification of lesions also makes them
vulnerable and in turn increases the risk for the rupture. Plaque rupture leads to thrombosis,
which may occlude the artery, and cause an ischemic attack or an infarction (Lusis, 2000). The
development of atherosclerotic lesion is demonstrated in figure 5.
Figure 5. Development of atherosclerotic lesion in human arteries. Macrophage staining (a,b) shows
infiltrated macrophages in the intima of the fatty streak lesion at the beginning of the atherosclerosis
process (a) and subsequent accumulation of macrophages in the shoulder area of the advanced lesion (b).
Smooth muscle actin staining (c,d) reveals the thickening of the intima in the fatty streak lesion (c) and
decreased  SMC  number  in  the  intima  of  the  advanced  lesion.  The  arrows  indicate  the  internal  elastic
lamina  between  the  intima  and  the  media,  and  asterisks  refer  to  the  necrotic  core  of  the  lesion.
Narrowing and the irregular structure in the lumen are seen in the advanced lesion (b,d).
2.3.2 Peripheral arterial disease
Peripheral arterial disease (PAD) is characterized by the narrowing or occlusion of lower
extremity arteries, most often due to atherosclerosis. The disrupted blood flow and oxygen
delivery in lower limbs leads to ischemia (Kumar et al., 2004). PAD can lead to pain during
walking (claudication), ulceration, rest pain and critical limb ischemia (CLI) (Norgren et al.,
2007a). Symptoms can be graded with Rutherford classification (0-6) as follows: stage 0
asymptomatic, 1 mild claudication, 2 moderate claudication, 3 severe claudication, 4 rest pain, 5
minor tissue lost, and 6 severe tissue lost or gangrene. Stages 0-3 are considered PAD and stages
4-6 the end stage of PAD, CLI (Varu et al., 2010). The prevalence of PAD ranges from 3 to 15 %
in  the  entire  population  (Norgren  et  al.,  2007;  Kasapis  and  Gurm,  2009).  Patient  with  CLI
represents 1 % of all PAD patients (Varu et al., 2010). PAD is more common in elderly people.
The known risk factors for PAD are elevated levels of serum cholesterol, smoking, high blood
pressure and diabetes. The ankle-brachial index (ABI), the ratio of highest systolic ankle
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pressure to the highest arm pressure (in mmHg), is the most widely used initial test to perform
when suspected PAD. The ABI ratio under 0.90 is considered abnormal, 0.71-0.90 and 0.40-0.70
indicate mild and moderate obstructions, respectively. The ABI ratio under 0.40 point to severe
obstructions (Kasapis and Gurm, 2009). In addition to PAD diagnosis, the ABI index has
prognostic value in the progression of the disease after treatment, identifying patients who are
at risk for critical limb ischemia, and cardiovascular morbidity and mortality (Hirsch et al.,
2006). Exercise testing, non-invasive imaging and angiography can be used for further diagnosis
of PAD (Kasapis and Gurm, 2009).
Treatment methods for PAD patients are surgical by-pass or angioplasty as well as drug
therapy but many of the patients are not suitable candidates for these treatments and 10-40 % of
patients may require leg amputation (Sneider et al., 2009; Ghosh et al., 2008). In addition,
patients presenting PAD have often coronary artery disease (CAD), which increases the risk for
cardiovascular events. Thus, new treatment strategies, such as gene therapy, are needed.
2.4 SKELETAL MUSCLE ENERGY METABOLISM
Occlusion of the main feeding artery in peripheral muscles clearly disrupts the energy
metabolism within the ischemic area. Normally, skeletal muscle is able to rapidly increase its
rate of energy consumption in situations where increased contraction is required. The increase
in energy production can be 300-fold from resting to  fully  activated contraction,  and this  can
occur within milliseconds (Sahlin et al., 1998). The fundamental energy source in muscle
activation is ATP. There is very little ATP actually stored in cells (5-6mM) and this is depleted in
a few seconds (Sahlin et al., 1998). Hence other metabolic pathways are needed. Energy
metabolism can be divided into the anaerobic and aerobic pathways. The former occurs under
low oxygen conditions and when rapid muscle activity is needed, and the latter process (aerobic
metabolism) occurs when oxygen is freely available and muscle contraction is prolonged and
submaximal  (Guyton and Hall,  2006).  The major  anaerobic  pathways to  generate  ATP are  the
degradation of phosphocreatine (PCr) and the  breakdown of glycogen to lactate and hydrogen
ions  (Westerblad  et  al.,  2010).  The  degradation  of  PCr  to  creatine  (Cr)  and  ATP  occurs  via
creatine kinase (CK). In conditions when ATP is being rapidly consumed, the PCr amount
declines, and the amount of Cr and inorganic phosphate (Pi) increase. During the recovery from
exercise, PCr is synthesized and the normal levels are restored (Westerblad et al., 2010c). ATP
levels remain rather constant in muscle tissue, and the intracellular ATP concentration does not
decrease below 60 % of the resting concentration, even during an intense exercise (Westerblad
et al., 2010). Glycogen breakdown occurs by phosphorylases which release glucose which can
undergo  glycolysis  and  pyruvate  conversion.  Lactate  dehydrogenase  converts  pyruvate  to
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lactate, and at the same time, hydrogen ions accumulate and decrease muscle pH from ~7.0 to
~6.5  (Westerblad et  al.,  2010).  In  the aerobic  pathway,  oxidative metabolism of  carbohydrates
and lipids is the main ATP-producing system (Spriet and Watt, 2003). The effects on energy
metabolism can be measured with phosphorus magnetic resonance spectroscopy in both
preclinical studies and in the clinic (Korpisalo et al., 2008; Greiner et al., 2006).
2.5 CARDIOVASCULAR GENE THERAPY
2.5.1 Principles of angiogenic gene therapy
Gene therapy means the delivery of genetic material into cells to achieve a therapeutic effect. In
angiogenic  gene  therapy,  the  transfer  of  genetic  material  can  be  used  to  rescue  tissue  from
hypoxia and ischemia by overexpressing factors which are intended to increase collateral vessel
growth and improve perfusion (Yla-Herttuala and Alitalo, 2003). Angiogenic gene therapy is a
potential treatment for patients suffering from PAD or CAD but who are not candidates for the
current therapies because of diffuse CAD or poor health status. Gene therapy may also be used
in conjunction with bypass surgery and angioplasty. The main advantages of gene therapy are
that administration of the gene drug is local and it is endogenous proteins which are being used
to treat the disease. A single administration of the gene drug can achieve a long lasting local
effect without side effects which could arise from its systemic administration (Yla-Herttuala and
Alitalo, 2003).
2.5.2 Gene transfer vectors and delivery routes
Gene transfer vectors and delivery routes are important factors to achieve the best gene therapy
result. Different vectors have their own advantages and disadvantages. The characteristics of
the most common vectors used in cardiovascular gene therapy are summarized in table 1. The
first cardiovascular gene therapy studies were conducted with naked plasmid DNA. Plasmid
DNA is easy to produce but unfortunately its efficacy is very low. Instead, viruses are effective
tools to deliver genetic material to cells. A critical issue when using genes as therapeutic drugs
is that the therapeutic gene should enter the cell nucleus and initiate transcription. It is also very
important to pay attention that one has the correct dose of the gene drug. Direct extrapolation
from animal experiments to man are always problematic, but they do at least suggest an
effective dose for humans. However, finding the correct dose for patients still remains a key
18
problem (Karvinen and Yla-Herttuala, 2010). Virus production is more challenging than
plasmid production. Good quality of virus preparations in preclinical studies can prevent false
effects; some effects in the past may have been attributable to impurities. Extrapolation between
species is another problem. Studies conducted in small rodents have often been promising, but
have failed when transferred to larger animals (Yla-Herttuala and Alitalo, 2003; Markkanen et
al., 2005). The target organs for proangiogenic cardiovascular gene therapy are the arteries,
veins, myocardium and skeletal muscles of the lower limbs. In animal studies intravenous (i.v.)
delivery of the gene drug is mostly used. This may be a convenient method, but the large blood
and tissue volumes in humans reduce the usefulness of this delivery route as a clinical
applications (Karvinen and Yla-Herttuala, 2010). Intra arterial gene transfer did not offered
increase in transduction efficiency compared to direct intramuscular (i.m.) injections (Korpisalo
et al., 2010). Gene drugs can be delivered effectively via catheters into the heart or by i.m.
injection into peripheral muscles (Yla-Herttuala and Alitalo, 2003). Direct injections into
myocardium and into the lower limb skeletal muscles are the most efficient delivery routes to
produce high expression of transgene, but the target areas need to be carefully selected to
ensure that the injections can reach the ischemic border areas where new blood vessel formation
is desirable (Karvinen and Yla-Herttuala, 2010). Catheter mediated intramyocardial injections
guided with an electronical 3D mapping system have recently been proven to be both safe and
practical (Lahteenvuo et al., 2009; Stewart et al., 2009). Ultrasound guidance can also be used to
target the injections into the lower limb skeletal muscles.
2.5.3 Viral vectors
2.5.3.1 Adenovirus vectors
Adenoviruses (Ad), 70-90 nm in diameter, are linear double stranded non-enveloped DNA-
viruses which cause airway and intestine infections. They enter cells via the Coxsackie-
adenovirus receptor (CAR), and integrins αVβ3 and αVβ5 (Bergelson et al., 1997; Wickham et al.,
1993).  The first generation Ad vectors have deletions in virus genome areas E1 and/or E3 which
mean that they are incapable of producing new virus particles in transduced cells. The
transgene capacity of the first generation adenoviral vector is about 7 kb  (Russell,  2000). Ads
are easy to produce in large scale cell culture systems and they have been widely used in gene
therapy  applications.  The  advantage  of  adenoviruses  is  their  capacity  to  transduce  both
dividing and non-dividing cells with high efficacy. Disadvantages of adenoviruses include
immunogenicity and formation of neutralizing antibodies (Russell, 2000). Modification of
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immunogenicity has been achieved but the potency of modified adenoviruses in gene therapy
applications in humans remains unknown (Wen et al., 2004).
2.5.3.2. Adeno-associated virus vectors
The adeno-associated virus (AAV) is a small single-stranded (25 nm) non-enveloped DNA virus
which belongs to parvovirus family. The infection of wild type AAV occurs only in the presence
of helper virus, adenovirus or herpesvirus. AAV can integrate site-specifically at chromosome
19 but current AAV vectors do not have this ability (Daya and Berns, 2008). Most AAV vectors
are based on AAV serotype 2 which enters into a cell using heparan sulphate proteolygans as
receptors  (Summerford  and  Samulski,  1998).  AAV  posesses  many  benefits  such  as
nonpathogenicity for humans, a wide range of infectivity depending on serotype, and a long
expression time (Wu et al., 2006; Daya and Berns, 2008; Warrington, Jr. and Herzog, 2006). AAV
transduction into the mouse heart can induce stable transgene expression in cardiomyocytes
without evoking inflammation (Svensson et al., 1999). The gene expression after AAV injections
can remain even many years (Niemeyer et al., 2009; Stieger et al., 2009). AAV serotypes have a
specific biodistribution in various organs. In terms of cardiovascular gene transfer, serotypes 1,
6, 8 and 9 seem to have the best transduction efficacy for heart and skeletal muscle (Palomeque
et al., 2007; Raake et al., 2008; Zincarelli et al., 2010; Xiao et al., 1999).
2.5.3.3. Lentivirus vectors
Lentivirus vectors are modified from human immunodefiency virus. Lentiviruses would be able
to induce stable gene expression via integration in to the genome. This may, on the other hand,
increase the risk for the activation of ongogenes. So far, the transduction efficacy of lentiviruses
in myocardium and in skeletal muscle has been low. (Kang et al., 2002; O'Rourke et al., 2003)
Some studies conducted with lentiviral gene transfer in cardiovascular models have revealed
slightly positive effects  (Niwano et al., 2008; Conklin et al., 2005).  However, lenti- and
retroviruses may well have use in gene therapy applications based on ex vivo gene transfer into
stem cells (Karvinen and Yla-Herttuala, 2010). Additionally, lentiviruses transduce efficiently
liver and neural cells, and thus  may represent a useful tool for other types of gene therapy
(Naldini et al., 1996; Trono, 2000).
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Table 1. Characteristics of the most common vectors used in cardiovascular gene transfer. Modified from
Rissanen et. al 2007
2.6 PRECLINICAL STUDIES
Before therapeutic gene transfer can be used to treat humans, preclinical studies are needed.
Cell culture studies, where the interactions between ligands, receptors and downstream
signaling can be characterized, can be used to acquire basic information. In vitro testing is also
an essential tool in any investigation of the functionality of gene transfer vectors. However, in
Vector Advantages Disadvantages
Non-viral vectors (plasmid
DNA, oligonucleotides)
Easy to produce
Safe
Short expression time
Low efficacy
Adenoviruses Easy to produce
High transduction efficacy
Relatively high transgene
capacity (~7 kb)
Short expression time (~14
days)
Inflammatory reactions
Immunity against virus
Adeno-associated virus
Transduces both proliferating
and quiescent cells
Long expression time
(months to years)
High transduction efficacy
Transduces both proliferating
and quiescent cells
Serotype specific tissue
tropism
Limited transgene capacity (~4
kb)
Laborious to produce in high
quantities
Safety of long-term gene
expression unclear
Lentivirus Long expression time
Transduces quiescent cells
Low immune response
Non-specific integration
Low transduction efficiency
Laborious to produce in high
quantities and titers
Retroviruses Long expression time
Relatively easy to produce
Non-specific integration
Transduces only dividing cells
Low immune response Low transduction efficiency
Laborious to produce in high
quantities and titers
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vivo testing in animal models is crucial if one wishes to study the actual effects of gene transfer
on tissues and organs in their natural environment.
There are many preclinical studies where the administration of growth factor genes, including
VEGF-A, -B, C, -D, and -E, PlGF, FGF-1, -2, -4 and -5, angiopoietins (Ang)-1 and -2, hepatocyte
growth factor (HGF), PDGF-A, -B, -C and –D, IGF-1 and -2, HIF-1α, and monocyte
chemoattractant protein-1 (MCP-1), have been shown to promote angiogenesis (Rissanen and
Yla-Herttuala, 2007). Most clinical trials for proangiogenic gene therapy have been conducted
by using VEGF-A (Yla-Herttuala et al., 2007). AdVEGF-A gene transfer has been shown to form
functional vessels in rabbit hindlimbs (Rissanen et al., 2005). Tissue-specific growth factors offer
improved gene transfer efficacy and good safety records. For example, VEGF-B has shown
cardiospecific potency in angiogenesis and also cardiospecific metabolic effects (Lahteenvuo et
al., 2009). Overexpression of VEGF-A can cause significant side effects, such as tissue edema
and uncontrolled vessel growth, which may limit the dose that can be administered. On the
other hand, maximal VEGF doses should be used to achieve physiological benefits. In recent
study, lower AdVEGF doses induced only angiogenesis while larger AdVEGF-A dose was
needed to enhance tissue metabolism (Korpisalo et al., 2010). Combinations of growth factors
have been studied in attempts to avoid side effects and improve physiological angiogenesis,. In
particular, Ang-1 has been shown to stabilize new blood vessels (Zacharek et al., 2007; Lamont
et al., 2010). Simultaneously administered AAV-VEGF-A165 and AAV-Ang-1 displayed an equal
angiogenic effect as AAV-VEGF-A165 alone,  but  considerably  reduced  the  leakage  of  the  new
vessels (Arsic et al., 2003). In addition to angiogenesis, VEGF gene transfer has been reported to
stimulate skeletal muscle regeneration in a mouse hind limb ischemia model (Arsic et al., 2004).
Recent study introduced that the drug-mediated regulation of AAV-VEGF expression improves
vascularization and perfusion in ischemic hind limb and the effects were able to persist upon
withdrawal of the angiogenic stimulus (Tafuro et al., 2009).  Combining AAV-PDGF-B with
AAV-VEGF-A achieved collateral vessel growth in rabbit hindlimb ischemia model and in pig
myocardium compared to AAV-VEGF-A, which induced only angiogenesis (Kupatt et al.,
2010).   Even though there have been several preclinical studies, the optimal delivery dose and
route of administration of VEGF-A have not yet been established. Further studies with new
strategies such as screening the optimal VEGF-A dose, studying and developing the best vector
for gene transfers into specific tissues and investigating long-term effects of VEGF-A gene
transfer will be important steps to be taken to meet this goal.
Transcription  factors,  such  as  HIFs  regulate  many  of  the  genes  involved  in  angiogenesis
(Hewitson and Schofield, 2004). Thus, virally delivered HIF could offer a more physiological
approach to induce therapeutic angiogenesis in ischemic tissues. It has been shown that
adenovirally delivered constitutively active HIF-1α increases muscle perfusion and collateral
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blood vessel formation in rabbit hindlimb ischemic skeletal muscles (Patel et al., 2005).
Additionally, in a mouse hind limb model HIF-1α delivered via AAV gene transfer has
achieved angiogenesis with less tissue edema compared to the administration of VEGF-A
(Pajusola et al., 2005). The potential benefits of HIF gene transfer on ischemic tissue metabolism
remain unknown.
2.7 CLINICAL TRIALS
To date there are no gene drugs that have been approved for clinical use in patients with cardi-
ovascular diseases. Most of the clinical trials have been done with VEGF-A, FGF4 and HIF-1α
using adenoviruses or plasmids as vectors (Yla-Herttuala et al., 2007; Gupta et al., 2009). The
first attempt to treat lower limb ischemia in the clinic by angiogenic gene therapy was per-
formed in 1996 (Isner et al., 1996). Gene transfer was conducted via intravascular administration
of the plasmid encoding human VEGF-A165.  Four weeks after  gene transfer,  improvements  in
collateral vessel growth and blood flow were observed. Subsequently, phase I studies done with
plasmid VEGF-A165 showed promising results in angiography, improved ankle brachial index
(ABI) and blood flow, and healing of wounds (Baumgartner et al., 1998; Isner et al., 1998;
Baumgartner et al., 2000). In placebo controlled phase II trial, adenoviral VEGF-A165 gene thera-
py in PAD patients was observed to be well tolerated and to increase vascularity (Makinen et
al., 2002).  Dose dependent effects of adenoviral gene transfer have also been reported. The in-
jection of a high dose of adenoviral VEGF-A121 increased tissue edema more than the low dose
in PAD patients, i.e. evidence that virally delivered growth factor had a dose dependent biolog-
ical effect (Rajagopalan et al., 2003).  The results from other phase II/III trials have not been very
promising. Most clinical trials using plasmid gene transfer have failed to reach their goals (Ris-
sanen and Yla-Herttuala, 2007; Gupta et al., 2009). Only one study done with the intra-arterial
administration of recombinant protein FGF-2 gene transfer (TRAFFIC) has shown a positive ef-
fect as measured by increased walking distance (Lederman et al., 2002). Clinical trials with ade-
noviruses have also been disappointing (Rissanen and Yla-Herttuala, 2007), with the exception
of  AdVEGF-A gene transfer  in  PAD patients  (Makinen et  al.,  2002).  Myocardial  gene transfer
has also been tried to treat ischemia. In the KAT trial, positive effects were obtained as adeno-
viral VEGF-A165 gene transfer increased myocardial perfusion in comparison to placebo (Hed-
man et al., 2003). Phase I trial (38 PAD patients) where i.m. injections of AdHIF-1α administra-
tion was used revealed good safety and evidences of of pain relief and ulcer healing (Rajagopa-
lan et al., 2007).  However, in a larger (289 patients), randomized, controlled trial in patients
with severe, intermittent claudication, no significant difference in the exercise treadmill test
23
time was observed between AdHIF-1α treatment and control groups (not published data yet)
(Gupta et al., 2009) .
2.8 SAFETY IN GENE THERAPY
Overall, angiogenic gene therapy has been shown to be well tolerated and safe in clinical trials
with no link to malignancies (Yla-Herttuala and Alitalo, 2003; Gupta et al., 2009).  An tragic
death occurred in 1999 after adenoviral gene transfer to a patient who suffered from a genetic
immune deficiency disease (Lehrman, 1999). Gene drugs, in the same way as other drugs and
therapies, are associated with side effects which depend on the administered vector, dose, route
of delivery, and properties of the transgene (Wirth et al.,  2006).  Adenoviral gene transfer has
been reported to be well tolerated, causing only mild fever in PAD patients (Makinen et al.,
2002).  Only  a  few  long-term  follow-up  studies  have  been  conducted.  After  the  KAT  trial
(Hedman et al., 2003), safety was followed for up to eight years after the primary gene delivery.
There were no differences between treated groups i.e. VEGF-adenovirus vs. VEGF
plasmid/liposome vs. placebo control in terms of health status or the incidence of major adverse
cardiovascular events (MACEs) or cancer (Hedman et al., 2009).  The clinical study where
myocardial injections of adenovirus encoding VEGF-A121 were administered with a NOGA
catheter also reveales a good safety profile (Stewart et al., 2009).
Gene therapy has mostly been used to treat elderly, no-option or end-stage cardiovascular
patients (Gupta et al., 2009). Angiogenic therapy may be more effective at an early disease stage
than in more severely ill patients. As reports of the safety of cardiovascular gene therapy
increase, researchers may now be able to perform trials in less morbid patients (Gupta et al.,
2009). Since it is a novel therapy, gene transfer is an expensive method, and only certain patients
will obtain more benefit than from traditional treatments. However, gene therapy is ethically
permissible for use in the treatment of complicated cardiovascular disorders. The gene transfer
applications used in the proangiogenic therapy are mainly based on adenoviruses and
plasmids, which induce the transient expression of transgene, and do not integrate into the
genome, decreasing the risk of the vertical transmission. Traditionally, therapies for treatment of
cardiovascular disorders must demonstrate improvements in morbidity or mortality; however,
patients may consider diminished quality, rather than quantity, of life which is the primary
detrimental factor in cardiovascular disease. Avoiding hospitalization and the other
manifestations of progressive disease could well be appropriate goals for angiogenic gene
therapy (Gupta et al., 2009).
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3 Aims of the study
I To characterize the expression of PDGF-C and PDGF-D and their receptors PDGFR-α
and PDGFR-β in human atherosclerotic lesions.
II To study the potential of AdPDGF-B gene transfer in angiogenesis and the stabilization
of vessels grown by AdVEGF-A gene transfer.
III To evaluate the long-term effects of AAV-VEGF-A gene transfer in normoperfused and
in ischemic hind limb skeletal muscles.
IV   To identify the angiogenic potential of AdHIF-2α and to evaluate the effect of HIF-
1α and HIF-2α on energy metabolism in ischemic hind limb skeletal muscles.
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4 Materials and methods
4.1 HUMAN ARTERIAL SAMPLES (Study I)
Human arterial samples were collected from amputations and autopsies from 25 to 84 year old
males and females. Arterial samples were immersion-fixed in 4 % paraformaldehyde and
embedded in paraffin for histological analysis or snap-frozen in liquid nitrogen and stored at -
70 oC for mRNA analysis. The protocol of this study was approved by the Ethical Committee of
the Kuopio University and the study conforms to all principles outlined in the Declaration of
Helsinki. Lesions (n=34) were classified into the following categories as: I normal, no lesion n=6,
II  fatty  streak  n=7,  III  plaque  n=  10,  and  IV  complicated  lesion  n=11.  The  evaluation  of  the
sections was done in a random order independently by two experienced researchers.
4.2 REVERSE TRANSCRIPTASE-PCR (Study I)
Total RNA was isolated from snap frozen artery samples with Trizol (Invitrogen, Carlsbad, CA,
USA) and RNA pellets were dissolved in sterile water containing 1 U/µl RNase Inhibitor (MBI
Fermentas,  Burlington,  ON,  Canada).  cDNA  synthesis  and  RT-PCR  were  conducted  as
previously described. Two µg of total RNA was used in cDNA synthesis. Samples were treated
with DNase (Promega, Madison, WI, USA) and cDNA synthesis was undertaken by using
random primers (Promega, Madison, WI, USA). Table 2 summarizes the primers used in the
study. PCR reactions contained 5 µl of 10×buffer including 1.5 mM Mg (Finnzymes, Espoo,
Finland),  1  µl  dNTP  (10  mM,  Finnzymes,  Espoo,  Finland),  1  µl  both  forward  and  reverse
primers (20 pmol), 0.5 µl Dynazyme II polymerase (Finnzymes, Espoo, Finland) added to 50 µl
sterile H2O. PCR reactions of 35 cycles were 45 s in 96 oC, 45 s in 54 oC for PDGFs or 58 oC for α-
actin  and  90  s  in  72oC. PCR products were detected in 1.2 % agarose gel. Samples without
reverse transcriptase were used as controls.
Table 2. RT-PCR primers
Gene Primers Sequence
PDGF-C Forward
Reverse
5'-TCACAGCCCAAGGTTTCC-3'
5'-GTCCAACTGCCATCTCTC-3'
PDGF-D Forward
Reverse
5'-TGACATGGCGGCTTCA-3'
5'-GTAACGCTTGGCATCATC-3'
α-actin Forward
Reverse
5'-ACCAACTGGGACGACATGGAAAA -3'
5'-GTCAGGATCTTCATGAGGTAGTC-3'
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4.3 IMMUNOHISTOCHEMISTRY (Studies I-IV)
In the immunostainings, 7 µm thick paraffin sections were cut. The antibodies and specific
stainings used in the study are listed in table 3. Avidin-biotin-Horse Radish Peroxidase (HRP)
system with diaminobenzidine (DAB) (Vector Laboratories, Burlingame, CA, USA) was used
for signal detection in single stainings and in double stainings, the second antibody was
detected by alkaline-phosphatase with Vector Blue colour substrate (Vector Laboratories,
Burlingame, CA, USA).
Table 3. Immunostainings
Antibody Specificity Clone/
code
Manufacturer Dilution Pretreatment Study
CD31 Endothelium JC70A Dako 1:50 - II-IV
Griffonia
simplifolia
lectin I
Endothelium B-1105 Vector 1:100 - unpublished
αSMA Smooth
muscle,
pericytes
1A4 Sigma 1:500 - II-IV
HHF-35 Smooth
muscle
C34931 Enzo Life
Sciences
1:50 - I
CD68 Macrophages KP1 Dako 1:250 - I
RAM11 Macrophages M0633 Dako 1:500 - II,III
PDGF-B PDGF-B AF-220-
NA
R&D Systems 1:500 Citrate boiling II
PDGF-C Human
PDGF-C
U. Eriksson 0,5 µg/ml Citrate boiling I
PDGF-C PDGF-C AF1560 R&D Systems 1:100 - I
PDGF-D Human
PDGF-D
U. Eriksson 0,5 µg/ml Citrate boiling I
PDGF-D PDGF-D AF1159 R&D Systems 1:100 - I
PDGFR-α PDGFR-α Sc-338 Santa Cruz 1:250 Citrate boiling I
PDGFR-b PDGFR-b Sc-6252 Santa Cruz 1:250 Citrate boiling I,II
VEGF-A VEGF-A121-206 C-1 Santa Cruz 1:500 - II-IV
VEGFR-1 VEGFR-1 sc-316 Santa Cruz 1:250 Citrate boiling II,IV
VEGFR-2 VEGFR-2 sc-6251 Santa Cruz 1:250 Citrate boiling II,IV
HIF-1α HIF-1α NB-100-
123
Novus
Biologicals
1:200 - IV
HIF-2α HIF-2α NB100-
132
Novus
Biologicals
1:200 - IV
eNOS eNOS 610296 BD BioSciences 1:50 - IV
Ki67 Proliferating
cells
MIB-1 Dako 1:100 Citrate boiling II-IV
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Hematoxylin-eosin staining was used to characterize tissue morphology (Studies II-IV). Specific
staining for glycogen Periodic acid-Schiff staining (PAS) was used to evaluate the amounts of
glucose in skeletal muscle (study IV) and masson trichrome staining was used to study the
formation of fibrosis (unpublished).
4.4 IN SITY HYBRIDIZATION (Study I)
The localization of PDGF-C and PDGF-D mRNA was studied by non-radioactive in situ hy-
bridization (Roche Diagnostics Co., Mannheim, Germany) from paraffin sections (Study I). Di-
goxigenin- (DIG) labelled antisense and sense probes for PDGF-C and PDGF-D were synthe-
sized according to the manufacturer's protocol. Paraffin sections were pretreated with Pro-
teinase K (Roche Diagnostics Co., Mannheim, Germany) (10 µg/ml). Hybridization of slides was
made in hybridization buffer (40 % deionized formamide, 10 % dextran sulfate, 1 × Denhardt's
solution, 4 × saline sodium citrate buffer (SSC), 10 mM dithiothreitol,  1 mg/ml yeast t-RNA, 1
mg/ml denatured ssDNA) containing antisense or sense probes at a concentration of 0.33 ng/µl
overnight at 58°C. After hybridization, the slides were washed in a shaking water bath at 58°C
with a decreasing SCC concentration. Immunological detection of DIG-labelled probes was
done according to the manufacturer's protocol (Roche Diagnostics Co., Mannheim, Germany)
using anti-DIG-alkaline phosphatase Fab fragments (Roche Diagnostics Co., Mannheim, Ger-
many). The colour reaction was detected with Nitro blue tetrazolium chloride/ 5-Bromo-4-
chloro-3-indolyl phosphate, toluidine salt (NTB/BCIP) solution (Roche Diagnostics Co., Mann-
heim, Germany).
4.5 ISCHEMIA OPERATIONS (Studies II-IV)
Two surgically induced models of acute ischemia in rabbits were used in this thesis work (Fig-
ure 6). Ligation of arteria femoralis profunda (Rissanen et al., 2005) was used in studies II and
III, and the ligation of arteria femoralis superficialis (SFA) with additional ligations to block ex-
cessive native collateral growth (Rissanen et al., 2003) in study IV. The ligation of PFA was op-
erated according to the previous description (Rissanen et al., 2005). The procedure was done
under ketamine (Ketalar 20 mg/kg, Pfizer, Finland) and medetomidine (Domitor 0.3 mg/kg,
Orion, Finland) anesthesia. The rabbits were given Carprofen (Rimadyl 0.1 mg/kg, Pfizer,
Finland) for post-operation pain. In this model, the thigh area becomes mildly ischemic but the
calf remains normally perfused. The ligation of SFA was also carried out as in the previous
study (Rissanen et al., 2003) one day before gene transfer. SFA and the re-entry branches for the
collateral blood vessels growing from the lateral circumflex and deep femoral arteries were li-
gated. This model results in a severe ischemia in the calf region but the thigh remains normally
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perfused. All animal experiments were approved by the Experimental Animal Committee at the
University of Kuopio.
Figure 6. Ischemia operations (Korpisalo 2009)
4.6 GENE TRANSFER (Studies II-IV)
The gene transfer  was performed by intramuscular  (i.m.)  injection into the hind limb skeletal
muscles of New Zealand White rabbits (studies II and IV) under ketamine (Ketalar 20 mg/kg,
Pfizer,) and medetomidine (Domitor 0.3 mg/kg, Orion, Finland) anesthesia.  First generation
serotype 5, adenoviral vectors, which had been tested first in vitro, were used with a viral dose
1×1011 vp/ml. Serotype 2 AAV viruses were used in study III with a viral dose of 1×1011 vg/ml.
All of the viruses used in these studies have the cytomegalovirus (CMV) promoter. Intramuscu-
lar (i.m.) injections into rabbit hind limb were performed in ten 0.1 ml injections using a 1 ml
syringe and a 25G needle.
The mouse myocardium model was also used in this thesis. During the myocardial injections,
57Bl6Ja mice were under the isoflurane inhalation anesthesia (induction: 4.5 % isoflurane, 450
ml air, maintenance: 2.0 % isoflurane, 200 ml air, Baxter International Inc., Deerfield, IL, USA).
AdLacZ, AdHIF-1α, AdHIF-2α, AdPDGF-C and AdPDGF-D were tested in the mouse heart.
Myocardial injections into the anterior wall of the left ventricle were performed under
ultrasound guidance with viral dose 1x1010 to 4x1010 vp. The injections were carried out as
previously  described  (Springer  et  al.,  2005;  Huusko  et  al.,  2010).  The  gene  transfer  was  done
with a microinjector using a 50 µl Hamilton syringe and a 30G needle. Carprofen (50 mg/ml,
Rimadyl, Pfizer, Finland) was given for analgesia after the procedure. The effects of the gene
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transfers were studied at predetermined time points i.e. 6, 14, 28 days or 6 and 12 months after
gene transfers. Table 4 summarizes the gene transfers carried out in this thesis work.
Table 4. Summary of gene transfers
Study Animal Ischemia
operation
Gene transfer Total dose Transduced
muscles
Time
points
II Rabbit PFA ligation AdLacZ
AdVEGF-A
AdPDGF-B
AdVEGF-A +
AdLacZ
AdVEGF-A +
AdPDGF-B
1011 vp
2×1011 vp, for
combinations
semimembranosus d6, d14,
d28
III Rabbit PFA ligation AAV-LacZ
(control)
AAV-VEGF-A
1011 vg semimembranosus 1 month,
6 months
12 months
IV Rabbit SFA ligation AdLacZ
AdVEGF-A
AdHIF-1α
AdHIF-2α
3×1011 vp semimembranosus
cruris cranialis
quadriceps femoris
tibialis anterior
gastrocnemius
d6, d14
Unpub
lished
Mouse - AdLacZ
AdHIF-1α
AdHIF-2α
AdPDGF-C
AdPDGF-D
1010 to 4×1010
vp
myocardium, left
ventricle anterior
wall
d6
Rabbit PFA AdPDGF-C
AdPDGF-D
1011 vp semimembranosus d6, d14
4.7 ULTRASOUND IMAGING (Studies II-IV)
Three different ultrasound approaches were used to assess skeletal muscle perfusion: Native
Doppler ultrasound (studies II-IV), Contrast enhanced Doppler (CEU) (study II) and contrast
pulse sequence ultrasound (studies III and IV). All ultrasound imaging was performed with the
Acuson Sequoia 512 system and a linear 15L8 transducer (Siemens). In the CEU and CPS
experiments, a second generation contrast agent, sulfur hexafluoride in a phospholipid shell,
(diameter 2.5 µm, SonoVue, Bracco) was used. Native Doppler imaging was performed without
contrast agent at the following parameters: 12.5 frames/s, power Doppler 14 MHz, dynamic
range 20 dB, power -5 dB, gain 50 and depth 20 mm. For CEU transversal plane video clips of 20
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s were captured using the power Doppler (mechanical index =0.6) mode at 8.5 MHz (dynamic
range  10  dB,  power  -18  dB,  mechanical  index  0.60,  gain  40  and  depth  20  mm)  with
administration of 0.3 ml bolus of SonoVue via the ear vein. The CPS method uses non-linear
fundamental frequencies, which result in better spatial resolution and high sensitivity to the
contrast media, and this provides improved tissue subtraction than the previous ultrasound
perfusion imaging techniques (Phillips and Gardner, 2004).   Transversal images of
semimembranosus muscles of both limbs were captured after a single bolus (0.5 ml) of SonoVue
contrast microbubbles (Bracco, Milan, Italy) with the following parameters at 8.0 MHz: power -
16dB, mechanical index 0.31, CPS gain -10 and depth 20 mm (Rissanen et al., 2008). Muscle
perfusion was quantified with DataPro 2.13 software (Noesis, Courtaboeuf, France) and the
perfusion ratio between transduced muscle and intact muscle was quantified using the maximal
signal intensities as previously reported (Rissanen et al., 2008).
A high-resolution imaging system specially developed for small animal research (Vevo 770,
VisualSonics  Inc.,  Toronto,  ON,  Canada)  was  used  to  capture  ultrasound  data  from  the  mice
myocardium on the injection day (d0) as well as six days after injection (d6). A high-frequency
ultrasound probe (RMV-707B) operated at 30 MHz, with a focal depth of 12.7 mm from the skin
surface. Ejection fraction and fractional shortening were determined from transversal short-axis
M-mode measurements and calculated by Vevo770 software (Huusko et al., 2010).
4.8 31PHOSPHORUS –MAGNETIC RESONANCE SPECTROSCOPY (Study IV)
The degree of ischemia and the level of anaerobic metabolism (anaerobic capacity) of rabbit calf
muscles before the ischemia operation, and 6 days after gene transfer were evaluated using
31Phosphorus –magnetic resonance spectroscopy (31P-MRS) according to the previous study
(Korpisalo et al., 2008a). 31P-MRS was performed with a UNITYINOVA imaging console (Varian)
interfaced with 4.7. T horizontal magnet (Magnex Scientific) with actively shielded gradients
(Magnex Scientific). A linear surface coil consisting of two separated loops tuned to 1H and 31P
frequencies was used for reception (1H, 200 MHz and 31P, 80.9 MHz, RAPID Biomedical,
Rimpar, Germany). The region of interest under the surface coil was adjusted using 1H signal
and 31P data were acquired after ~70 degree hard pulse excitation using repetition time of 1.5 s,
spectral band of 10 kHz covered by 4096 data points and number of averages of 16. Small
needle electrodes (27 G) were placed on both sides of the sciatic nerve on the lateral side of the
rabbit thigh. During the whole duration of the experiment (20 min), 31P-MRS spectra were
collected, each scan taking 30 s. First, base line spectra from resting muscle were collected for 2
min. Thereafter, the sciatic nerve was electrically stimulated for 6 min at 3 Hz using a voltage of
150 V (14A11 Electromyograph, Disa) to induce maximal contraction in the calf muscles. Then
the stimulation was stopped and muscle recovery was followed for 12 min. Line shape fitting
analyses of spectra after pre-processing the data by discarding the two first data points, using a
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DC correction of 500 and 15 line broadening were performed by using JMRui 2.1. software. The
ratio between the peak areas of phosphocreatine (PCr) and the sum of PCr and inorganic
phosphate (Pi) i.e. PCr/(PCr+Pi) was calculated and used as a measure of anaerobic capacity and
fatigue. Results are presented as means from baseline (0-2 min), the last two minutes of the
exercise (6-8 min) and the last two minutes in the end of the procedure, recovery stage, (18-20
min).
4.9 TISSUE EDEMA (Studies II-IV)
Modified Miles assay was used to evaluate the leakiness of newly formed vessels (Rissanen et
al.,  2005).  Evans  Blue  dye  (30  mg/kg)  binding  to  plasma  proteins  was  injected  30  min  before
euthanasia via the ear vein. After euthanasia, animals were perfusion-fixed with 1 %
paraformaldehyde in 0.05 M citrate buffer, pH 3.5, via the left ventricle. Muscle samples were
taken from both transduced muscles and contralateral intact muscles and weighed. Evans Blue
dye was eluted in formamide and the released dye was quantified with a spectrophotometer at
610 nm. Absorbances were normalized to sample weights and the ratio between transduced and
intact muscle samples was calculated reflecting the permeability of neovessels.
4.10 HISTOLOGICAL ANALYSIS (Studies II-IV)
For evaluating capillary growth, mean capillary area (µm2) was measured. Photographs for
analysis were taken with an Olympus AX70 microscope (Olympus Optical, Tokyo Japan). Ten
images of 200 x magnification were taken from each CD31 stained section, and the mean
capillary area (µm2) was measured using the AnalySIS software (Soft Imaging System,
Muenster, Germany). Capillary and myocyte numbers and the capillaries/myocytes ratio were
counted from the same photographs. All measurements were performed in a blinded manner.
4.11 PROTEIN EXPRESSION (Studies II-IV)
Samples from transduced muscles and non-transduced safety tissues, the heart, lungs, liver,
spleen, kidney, and ovaries or testis were snap frozen in liquid nitrogen and stored at -70oC.
Approximately 100 mg of tissue were lysed in T-PER tissue lysis buffer (Termo Scientific)
containing 1× Halt protease inhibitor cocktail (Termo Scientific) for protein expression analysis.
Tissue lyser (Qiagen) was used for the homogenization of the samples. Supernatants were
collected  and  used  in  ELISA  assays.  Anti-human  VEGF-A  and  PDGF-B  ELISA  kits  (R&D
Systems, Minneapolis, MN, USA) were used to measure VEGF-A and PDGF-B levels,
respectively, and the results were normalized to the total protein amount measured with BCA
kit (Termo Scientific). The Western blot analysis for protein expression in vitro was done for all
virus contructs used in the thesis work. In electrophoresis, 10-15µg of the total protein was
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separated in SDS-PAGE gel and proteins were blotted into a nitrocellulose membrane. Primary
antibodies and used dilution are the same as in the Table 3 except mab HIF-1α and -2α (1:400)
and goat polyclonal PDGF-C and –D (1:500). Proteins were visualized using horseradish
peroxidase-conjugated secondary antibody and ECL Plus detection system (GE Healthcare), and
detected with Typhoon 9400 (GE Healthcare) scanner.
4.12 STATISTICAL ANALYSIS (I-IV)
The results are presented as mean ± standard error of mean (SEM). Kruskall-Wallis test was
used to evaluate the statistical significance of the results followed with Mann Whitney-test as a
post-hoc test where appropriate with non-parametric data. (I-IV). One-way Anova and t-test
were used with parametric data. Significances are shown as follows *p<0.05, **p<0.01 and
***p<0.001. All statistical analyses were performed using GraphPad, version 4.03, software.
35
5 Results
5.1 GROWTH FACTOR EXPRESSION IN HUMAN ATHEROSCLEROTIC LESIONS (I)
The expressions of PDGF-C and PDGF-D and their receptors PDGFR-α and PDGFR-β in human
atherosclerotic lesions were studied. Altogether 34 human arterial samples were classified into
the following categories as: I normal, no lesion (n=6), II fatty streak (n=7), III plaque (n= 10), and
IV complicated lesion (n=11) according to the macrophage and smooth muscle actin stainings.
PDGF-C and PDGF-D immunostainings indicated that PDGF-C was expressed strongly in the
endothelium and macrophages in the intima of all stages of the lesion, whereas PDGF-D was
more diffusively expressed in the vessel wall (Figure 7a-d). In addition to protein
immunostainings mRNA expression of PDGF-C and PDGF-D was investigated in arterial
lesions since secreted growth factors could be produced elsewhere than in the arterial wall.
PDGF-C and PDGF-D mRNA expressions were detected by in situ hybridization in plaque
shoulder areas (Figure 7 inserts in b,d). RT-PCR confirmed the in situ hybridization results.
Figure 7. Expression  of  PDGF-C  and  PDGF-D  and  their  receptors  PDGFR-α and  PDGFR-β in  human
atherosclerotic lesions. PDGF-C and –D stainings in a normal artery wall (a and c, respectively) and in a
lesion (b and d respectively). The inserts in b and d reveal mRNA expression. PDGFR-α and -β stainings
in a normal artery wall (e and g, respectively) and in a lesion (f and h, respectively). Scale bar 100 µm
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Differences in the protein expression of PDGF-C and PDGF-D were measured by microscopical
semiquantitative analysis. Table 6 summarizes data from PDGF-C and PDFG-D stainings and
differences in the expression of the examined groups. PDGF-C staining was significantly
increased  (P=  0.041)  in  the  intima  of  fatty  streaks  compared  to  the  intima  of  normal  arteries.
There were no significant differences between normal and plaque groups or normal and
complicated lesion groups in PDGF-C stainings. PDGF-D staining detected no significant
differences between the examined groups. PDGF-C staining in normal artery ECs was
significantly higher than PDGF-D staining in ECs in normal arteries (P= 0.009). The P-values for
comparison between PDGF-C and PDGF-D stainings in ECs in fatty streaks was almost
statistically significant (P=0.07) and between PDGF-C and PDGF-D stainings in ECs in plaques
the corresponding value was 0.08.
Table 6. Mean scores of the semiquantitative evaluation of the atherosclerotic artery samples
Samples PDGF-C PDGF-D
EC Intima Media EC Intima Media
Normal 2,6 1,3 2,2 1,3 1,8 2,3
Fatty streak 2,1 2,4 1,4 1,1 2,2 1,9
Plaque 1,9 2,0 1,6 0,7 2,0 2,5
Complicated
lesion 2,0 1,9 1,4 1,7 2,3 2,2
Normal samples and atherosclerotic lesions were collected from aortas, coronary arteries and femoral
arteries of 25-84 year-old patients (n= 34). PDGF-C and PDGF-D stainings were evaluated as percen-
tage (%) of the microscopical section and divided into four categories; score: 0: no staining, score: 1:
less than 30 % of area stained, score: 2: 30-60 % stained, and score: 3: more than 60 % stained.
PDGFR-α and PDGFR-b expressions were also investigates in normal arteries and in
atherosclerotic lesions (Figure 7e-h). Positive PDGFR-α staining was seen in ECs, intima and
media in normal arteries (Figure 7e). In plaques PDGFR-α expression remained strong in the EC
layer and was moderate in the intima and the media (Figere 7f). Macrophages were
prominently positive for PDGFR-α in plaques (Figure 7f). PDGFR-b was expressed in SMCs in
normal arteries (Figure 7g). In the plaques macrophages in the shoulder area and the intima
displayed intense expression of PDGFR-b but less positivity was detected in medial SMCs
(Figure 7h).
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5.2 GENE TRANSFER FOR THERAPEUTIC ANGIOGENESIS (II-IV and unpublished results)
In an attempt to stimulate therapeutic angiogenesis, the angiogenic effects of viral gene transfer
in rabbit hindlimb model and in mouse myocardium were studied. Six different adenoviruses
encoding human VEGF-A, human PDGF-B, human PDGF-C, human PDGF-D, mouse HIF-1α
and mouse HIF-2α, and AAV encoding human VEGF-A were used. AdLacZ and AAV-LacZ
were used as controls.  The protein expressions of the viral constructs were analyzed by
Western Blot. The results from gene transfer studies on angiogenesis are summarized in Table 7.
Firstly, the angiogenic potency of AdPDGF-B was tested and compared to the effects of
intramuscular  gene  transfer  of  AdVEGF-A  or  AdPDGF-B  or  in  combination  on  pericyte
activation and the stability of angiogenic vessels in normoperfused and ischemic rabbit
hindlimbs (II). AdPDGF-B gene transfer increased perfusion significantly but remarkably less
than AdVEGF-A six days after gene transfer. However, the main response to AdPDGF-B gene
transfer, instead of angiogenesis, was the proliferation of cells in the muscle interstitium.
AdVEGF-A was shown to induce about a twenty-fold increase in skeletal muscle perfusion in
normoperfused limbs (II,IV) and an eight-fold increase in ischemic limbs compared to AdLacZ
control at six days after gene transfer (II).  At the six day time point, AdVEGF-A gene transfer
had evoked a major increase in mean capillary size, and the most newly formed capillaries were
covered with pericytes (II,IV). However, a side effect of this intense and sudden capillary
growth, was the presence of a significant tissue edema (II,IV). The combination of AdVEGF-A
and AdPDGF-B gene transfer increased skeletal muscle perfusion almost as much as AdVEGF-
A alone at six days but this was achieved with a less extensive increase in capillary size and
with a remarkabl higher degree of tissue edema compared to the AdVEGF-A administration
(II). While AdVEGF-A induced perfusion returned back to the baseline, both AdPDGF-B and
AdVEGF-A+AdPDGF-B induced perfusions were detectable fourteen days after gene transfer.
In addition, the extend of the increase in AdPDGF-B induced perfusion remained significantly
elevated 28 days after gene transfer (II). The effect of PDGF-B on the stability of blood vessels
grown by VEGF-A was also examined. Surprisingly, it was noted that rather than increasing
pericytes that were attached to new capillaries, administration of PDGF-B evoked the
detachment of pericytes which could be seen in confocal images. In addition, scattered,
interstitial located αSMA positive cells were seen in histology. For comparison, the new
capillaries were properly covered with αSMA positive pericytes in muscles transduced with
AdVEGF-A alone (Figure 8) (II).
Since PDGF-B showed a slight increase in angiogenesis the angiogenic potency of other PDGF
ligands, PDGF-C and PDGF-D was tested but these did not induce significant angiogenesis in
rabbit hind limbs, though minor increases in perfusion were observed in AdPDGF-C
transduced muscles six days after gene transfer. AdPDGF-C and AdPDGF-D were also been
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tested in mouse myocardium. In mouse myocardium, both AdPDGF-C and AdPDGF-D
increased mean capillary size compared with AdLacZ (4.5 and 5.0 vs. 3.5 µm2,P<0.05), but had
no favorable effects on myocardial function, ejection fraction or fractional shortening
(Unpublished results).
Adenovirally delivered HIF-1α and HIF-2α caused approximately four-fold increases in
perfusion and capillary size compared to AdLacZ in the rabbit hind limbs. The effects of HIFs
were modest compared to VEGF-A, but newly formed capillaries were uniform in shape, and
no visible tissue edema was detected in ultrasound imaging (IV). In comparison, AdVEGF-A
gene transfer, HIFs did not notably recruit interstitial cells but nevertheless new capillaries were
covered with αSMA positive pericytes. In mouse myocardium, adenovirally delivered HIFs
significantly increased the mean capillary area (µm2) compared to AdLacZ transduced
myocardium (6.0 and 6.5 vs. 3.4 µm2, P<0.01 and P<0.05) but no benefits were achieved in
myocardial function, ejection fraction or fractional shortening (Unpublished results). Figure 9.
presents the image of the ultrasound guided injection into the mouse heart and lectin staings
from AdPDGF-C, AdPDGF-D, AdLacZ, AdHIF-1α and AdHIF-2α transduced myocardiums.
Figure 8. CD31 (blue) + αSMA (brown) double staining shows that AdVEGF-A gene transfer induced
new vessels were coveraged by pericytes (a) while after AdVEGF-A+AdPDGF-B gene transfer (b)
αSMA positive cells were found in interstitium (arrowheads)  and some new vessels completely lack
pericytes (arrow). In confocal images αSMA positive pericytes (green) are associated with vascular
structures (red) of AdVEGF-A transduced muscles (c). In contrast, αSMA positive cells were often
found between vascular structures (asterisks) and directing away from vessels (arrowheads) after
AdVEGF-A+AdPDGF-B gene transfer.
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Table 7. Summary of angiogenic effects in rabbit hind limbs induced by several viral constructs
Ad-
LacZ
Ad-
VEGFA
Ad-
PDGF-B
AdVEGFA+
AdPDGF-B
Ad-
PDGF-C
Ad-
PDGF-D
Ad-
HIF-
1α
Ad-
HIF-2α
AAV-
LacZ
AAV-
VEGF-A
Doppler
(ratio to
intact)
1.3 34.1*** 4.3** 24.1*** 4.0* 2.3 1.8 1.8 0.1 9.4*
CPS
(ratio to
intact)
1.0 18.3* - - - - 3.8* 4.5* 0.3 10.8*
Capillary
area
(µm2)
6.9 178.5** 13.0 150.7** 16.1 13.3 29.0* 21.6* 13.5 38.4*
Edema
(Abs./g)
1.6 33.8** 3.8* 37.7** 3.3 2.9 1.9 2.1 0.9 3.3*
Recruit-
ment of
cells
None Moderate High High High High Very
mild
Very
mild
None Moderate
Effects of adenoviral (Ad) constructs are at six day time point and the effects of AAV at six months after
gene transfer. Recruitment of cells in the interstitial space is estimated from HE-stainings.
Figure 9. Gene transfers into mouse myocardium. Ultrasound guided injection into the anterior wall of
the left ventricle. Arrowhead indicates the needle and asterisk injected virus solution. Lectin stainings
from AdPDGF-C, AdPDGF-D, AdLacZ, AdHIF-1α and AdHIF-2α transduced myocardium at day 6.
Scale bar 50 µm.
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5.3 EFFECTS OF LONG-TERM VEGF-A EXPRESSION IN SKELETAL MUSCLE (III)
AAV-VEGF-A induced long-term angiogenesis in rabbit hind limbs. An approximately 10-fold
increase was observed in skeletal muscle perfusion which remained elevated for up to one year
(III). In addition to perfusion, other effects of the long-term AAV-VEGF-A expression were
studied in skeletal muscles. Slightly increased levels of VEGF-A could be measured by ELISA
from AAV-VEGF-A transduced muscles at one year, but no significant differences were found
in comparison to AAV-LacZ muscles (112 ± 60 pg/mg and 85 ± 39 pg/mg, respectively). VEGF-A
levels were also measured from non-transduced safety tissues: heart, lungs, liver, spleen,
kidney, and ovaries or testis, but no significant changes were observed between the study
groups. Immunostaining revealed VEGF-A expression in myocytes and enlarged capillaries
around VEGF-A expressing myocytes one year after gene transfer (Figure 10). When quantified,
increases in angiogenesis at the capillary level were detected in both the mean area of capillaries
(38.4±8.8 µm2 vs. AAV-LacZ 13.5±2.0 µm2) and capillaries per myocyte ratio (1.6±0.05 vs.
AAVLacZ 0.4±0.04) indicating the presense of both capillary enlargement and sprouting
angiogenesis. Only some new vessels were covered with an αSMA layer indicating that not all
formed vessels were stabilized. Additionally, long-term VEGF-A expression had recruited a
number of macrophages which may have induced further endogenous VEGF-A expression.
Importantly, dramatic changes in skeletal muscle morphology were seen in the histological
evaluation. Both atrophic and hypertrophic muscle fibers were observed in transduced areas
and there were high amounts of extracellular matrix and fibrosis. Interestingly, long-term
VEGF-A expression produced vascular-like structures inside the muscle fibers indicating the
presence of aberrant forms of neovascularization. Vascular-like structures containing red blood
cells were observed inside myocytes, but these structures did not have CD31 positive
endothelium one month after AAV-VEGF-A gene transfer. On the contrary, one year after
Figure 10. VEGF immunostaining showing VEGF-A  expression  one  year  after  AAV-VEGF-A
transduction (left)  and CD31 staining showing angiogenesis at the capillary level (right).  Arrowheads
point to VEGF-A positive myocytes and arrows show enlarged capillaries.
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AAV-VEGF-A gene transfer many of these vascular structures were covered by CD31-positive
ECs and no red blood cells were seen, which may be due to that they were flushed away during
perfusion fixation indicating connection to circulation.
5.4 STIMULATION OF PHYSIOLOGICAL ANGIOGENESIS (IV)
Due to the very intense angiogenic response of VEGF-A and side effects described above it was
speculated that it may not be the most optimal therapeutic gene. Therefore the therapeutic
potential of proangiogenic transcription factors HIF-1α and HIF-2α was examined. Perfusion
increase after AdHIF-1α and HIF-2α gene transfer was detected by Doppler and CPS
ultrasound methods, respectively. No tissue edema was observed and histology revealed
enlarged capillaries after AdHIF-1α and AdHIF-2α gene transfer. Figure 11 summarize CPS
perfusion and capillary enlargement after AAV-VEGF-A, AdVEGF-A, AdHIF-1α and AdHIF-2α
gene transfers.
Figure 11. The CPS perfusion and the capillary enlargement after AAV-VEGF-A, AdVEGF-A, AdHIF-1α
and AdHIF-2α gene transfer. AAV-LacZ and AdLacZ present the effects of the control viruses.
One aim of the AdHIF-1α and AdHIF-2α gene transfers was also to investigate if these factors
are capable of enhancing skeletal muscle metabolism. Energy metabolism was measured in an
ischemic rabbit hind limb skeletal muscle by 31P-MRS and it was observed that AdHIF-1α gene
transfer significantly enhanced the recovery of the ischemic tissue from the energy loss induced
by exercise. AdHIF-2α transduced muscles recovered similarly as intact muscles. Figure 12
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presents representative MRS spectra from baseline (0-2 min), exercise (2-8 min) and recovery (8-
20 min). In baseline, before the electrically stimulated exercise, the high PCr peak and ATP
peaks are visible (Figure 12 a). During the exercise the PCr peak declines and the PCi peak arise
(Figure 12 b).  In 12 minutes recovery time PCi peak declines and PCr stores are refilled
increasing the PCr peak in a spectrum (Figure 12 c).  In addition, quantified results from 31P-
MRS obtained from ischemic rabbit hind limbs after AdHIF-1α and AdHIF-2α gene transfer are
shown (Figure 12 d and e). Exercise declined PCr(PCr+Pi) ratio in all the study groups
compared to baseline (P<0.001) before and six days after gene transfer (Figure 12 d and e). At
day 0 only intact muscles were able to recover while PCr(PCr+Pi) ratio in operated muscles
before gene transfer remained close to the same as under exercise (operated muscles vs. intacts
P<0.01and P<0.001) (Figure 12 d). Six days after gene transfer, ischemic muscles were also able
to recover, but PCr(PCr+Pi) ratio in AdLacZ muscles remained still significantly under the value
of intact muscles (P<0.05). AdHIF-1α transduced muscles recovered significantly better that
AdLacZ muscles (P<0.01). PCr(PCr+Pi) ratio in AdHIF-2α muscles after the exercise recovered
back to the baseline.
Figure 12. Representative MRS scans from rabbit hind limb skeletal muscle, Baseline (a), Exercise (b) and
Recovery (c). Quantified 31P-MRS data one day after ischemia operation (d0) (d) and six days after gene
transfer (d6) (e).
43
6 Discussion
6.1 GROWTH FACTOR EXPRESSION IN ATHEROSCLEROTIC LESIONS
Atherosclerotic lesions occlude arteries in the periphery and lead to a progressive impairment
of blood supply. Today, treatments for PAD patients are somewhat limited and new strategies
are  needed  (Ghosh  et  al.,  2008;  Sneider  et  al.,  2009).  Gene  therapy  and  the  delivery  of
proangiogenic growth factors into ischemic tissue could be a novel treatment for PAD patients
(Yla-Herttuala and Alitalo, 2003). The optimal gene to deliver should not only open the
collaterals surrounding the occluded artery but it should also be able to reduce the progression
of atherosclerosis in the diseased artery. Thus, studying the expression profiles of growth
factors in lesions provides important information about which factors are involved in normal
vascular biology and which factors are linked to diseases. This thesis has examined the
expression profile of novel PDGF family members, PDGF-C and PDGF-D. It has been reported
previously that PDGF-C and PDGF-D are expressed in advanced carotid atherosclerotic lesions
and they have effects on monocyte migration and the expression of matrix metalloproteinase-2
and -9 (Wagsater et al., 2008). Here their expression pattern has been characterized more
comprehensively and it was observed that both of these factors were intensely expressed in
normal human arteries, fatty streaks, early lesions as well as in advanced lesions. The results
from these studies are descriptive but important for gene therapy applications if it is considered
to  use  PDGF-C  or  –D.  Both  of  these  factors  seem  to  have  a  function  in  normal  vascular  wall
maintenance rather than in the progression of atherosclerosis. In addition, PDGF-C may have
some impact on the formation of the fatty streak because PDGF-C levels were significantly
elevated in fatty streak ECs. Further studies in animal models will be needed to investigate this
hypothesis in more detail. In transgenic mouse models, increased levels of PDGF-C and –D
have  been  shown  to  cause  pathological  changes.  Both  PDGF-C  and  PDGF-D   are  strong
stimulators of tissue fibrosis (Ponten et al., 2003; Ponten et al., 2005). Additionally, recent
studies have also implicated both PDGF-C and PDGF-D in pathological angiogenesis in mice
models  (Hou  et  al.,  2010;  Kumar  et  al.,  2010).  The  present  results,  as  well  as  the  results  from
mouse studies above, indicate that the therapeutic window of PDGF-C and -D is relatively
narrow, i.e. overexpression with adenoviral gene transfer does not improve vascular function,
and more efficient overexpression simply causes tissue fibrosis.
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6.2 THERAPEUTIC OUTCOME OF GENE TRANSFERS
Vessel maturation is a key issue in the outcome of angiogenic gene therapy. Newly formed
vessels should feed the ischemic area and the opened collateral vessels should stay patent for
the rest of the patient’s life. Adenovirally delivered VEGF-A expression is transient, and after
VEGF-A withdrawal, angiogenesis returns back to the basal level at least in normoxic muscles
(Rissanen et al., 2005; Vajanto et al., 2002). It has been reported that the stabilization of newly
formed vessels occurs after a few weeks of VEGF-A expression and tissue perfusion is
permanently elevated even after cessation of VEGF-A expression. (Zentilin et al., 2006b; Dor et
al., 2002). Thus, growth factor expression and its effect need to be long enough to achieve a real
therapeutic impact. Here the ability of combined PDGF-B and VEGF-A gene transfer to stabilize
VEGF-A driven angiogenesis was studied. PDGFs recruit pericytes, and induce SMC
proliferation and migration and may therefore stabilize vessels and decrease edema (Cao et al.,
2003; Uutela et al.,  2004). In the present study, PDGF-B prolonged angiogenesis in rabbit hind
limb but this seemed to be mediated by recruitment of interstitial cells i.e. it appeared to be the
paracrine  effect  of  growth  factors  secreted  by  these  recruited  cells  rather  than  direct  vessel
maturation. Pericyte coverage of new vessels was seen in AdVEGF-A transduced muscles and
even pericyte detachment was detected in AdVEGF-A+AdPDGF-B transduced muscles.
Apparently, VEGF-A and PBGF-B were not expressed in the same cells and this hampered the
therapeutic effect of the combination gene transfer. Previous reports have indicated that the
correct PDGF-B gradient is required for optimal pericyte recruitment and vessel maturation
(Abramsson  et  al.,  2003;  Lindblom  et  al.,  2003).  Recently,  the  role  of  the  two  novel  growth
factors, PDGF-C and PDGF-D, in angiogenesis has been investigated. PDGF-C has been
reported to induce angiogenesis in a mouse model (Li et al., 2005). Here capillary growth was
detected in the mouse heart but in the rabbit model only very mild angiogenic effect was noted,
evidence for the poor angiogenic efficacy of PDGF-C in a larger animal. There are similar
observations after adenoviral PDGF-D gene transfer in the mouse heart and in rabbit hind limb.
PDGF-D may have a positive effect on angiogenesis since it is known to induce vessel
maturation when used in combination with VEGF-E in gene transfer (Uutela et al., 2004).
Recruitment of interstitial cells, mostly fibroblasts, after AdPDGF-C and –D gene transfer was
signicant in rabbit skeletal muscles, indicating a similar limitation to the therapeutic use as
discussed above.
Unwanted events can occur when angiogenic growth factor is expressed constitutively in tissue.
Here the effects of long-term VEGF-A expression were monitored in rabbit hind limb and it was
observed that angiogenesis remained elevated for up to one year but in addition, long-term
VEGF-A expression evoked severe problems in skeletal muscle morphology, formation of
extracellular matrix, hypertrophy or atrophy of myocytes, infiltration of mononuclear cells and
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the formation of vascular structures inside muscle fibers. It should be noted that enhanced
extracellular matrix is proangiogenic, but fibrosis may also decrease the flexibility and
contractility of skeletal muscle. Long-term VEGF-A expression recruited macrophages, and
these cells can promote endogenous expression of VEGF-A leading to prolonged and enhanced
angiogenesis. Previously, VEGF-A has been shown to be able to recruit mononuclear cells via
VEGFR-1 and Nrp-1 stimulation, evidence for the positive role of the paracrine secretion of
these cells (Zentilin et al., 2006; Zacchigna et al., 2008). Only a few VEGF-A positive cells were
seen in the transduced muscles one year after the gene transfer but local, even low, expression
of VEGF-A could be possibly sufficient to maintain active angiogenesis for long periods of time.
The other  option is  that  the vessels  have been maturated as  shown previously by a  model  of
conditional switching of VEGF expression (Dor et al., 2002). The AAV-VEGF-A driven negative
effects in skeletal muscle need to be taken into account. Aberrant vascular structures inside
muscle fibers are not a desirable outcome of therapeutic angiogenesis. One possible explanation
for  these  vascular  lacunae  could  be  that  the  AAV-VEGF-A  transduced  myocytes  had  been
recognized and destroyed by the immune system and their remnants had been vascularized.
Additionally, AAV has a high natural tropism towards skeletal muscle (Warrington, Jr. and
Herzog, 2006b), which in this case may cause too efficient transgene expression in muscle cells
leading to abnormal tissue structures. Some similar structures have been reported at shorter
time points (Arsic et al., 2003; Zacchigna et al., 2007).
In comparison, adenoviral VEGF-A gene transfer increased perfusion up to 20-fold but the
effect of AdVEGF-A was transient lasting about two weeks. In contrast, AAV-VEGF-A induced
a 10-fold increase in perfusion, and the effect of AAV can last for years. With adenovirus, the
muscle area can be efficiently transduced since it spreads evenly after an injection. The effect of
AAV is very local due to AAV binding to heparan sulfate proteoglycans expressed on cell
surface (Summerford and Samulski, 1998) and this may limit the efficient transduction so that it
does not cover the muscle properly. Transient and a very strong AdVEGF-A expression evoked
tissue edema but AAV-VEGF-A expression had side effects as well, although the edema was not
significant. AAV-VEGF-A caused tissue fibrosis and muscle disorganization which are
disadvantages reducing the suitability of this construct for therapeutic use. Apart from the
findings at the local site of gene transfer, the general safety of the intramuscular AAV-VEGF-A
gene transfer in rabbit hindlimb appeared to be acceptable. There were neither increased levels
of human VEGF-A found in ectopic organs nor were any histological differences detected
outside of target muscles in AAV-VEGF-A animals compared with AAV-LacZ animals. This is
important for the safety of VEGF-A gene therapy because systemic long-term expression of
VEGF-A has been reported to induce tumor formation and bleeding in tissues (Leppanen et al.,
2006).
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HIF-1α gene transfer has been shown to induce angiogenesis but have fewer side effects than
VEGF-A gene transfer (Pajusola et al., 2005). The increase in permeability and tissue edema are
strongly linked to capillary enlargement (Rissanen et al., 2003). In this present study, no
harmful tissue edema was observed after AdHIF-1α or AdHIF-2α gene transfer. However,
capillary growth and skeletal muscle perfusion were significantly improved indicating that
enhanced angiogenesis can be achieved without any major tissue edema.
 6.3 GENE TRANSFER FOR STIMULATING ENERGY METABOLISM
An optimal gene transfer construct for ischemic tissue would improve not only angiogenesis
but also tissue metabolism, therefore the capacity of HIFs to influence ischemic skeletal muscle
metabolism and recovery from exercise was evaluated. Previously, AdPlGF gene transfer has
been shown to improve energy metabolism during exercise (Korpisalo et al., 2008). Both
AdHIF-1α and AdHIF-2α improved the recovery from the energy loss induced by exercise in
comparison to AdLacZ. The effects on skeletal muscle metabolism were evaluated by 31P-MRS,
and PCr and Pi levels were used to measure the skeletal muscle recovery. AdHIF-1α
significantly enhanced the capacity of the muscles to refill PCr storage after exercise, whereas
the recovery of AdHIF-2α transduced muscles was similar to the situation in intact muscles.
PCr stores are not properly refilled in 20 minutes, which explains the smaller PCr peak in
recovery stage compared to the baseline PCr peak.  The positive effect on energy metabolism
indicates that vessels grown under the influence of the transcription factor gene transfer
function normally and the 4-fold increase in angiogenesis, as measured with ultrasound
techniques and histological analysis, is believed to be sufficient to improve PCr based ATP
synthesis and to restore and replenis PCr stores rapidly after exercise. The results from 31PMRS
indicate that HIFs have an effect on anaerobic metabolism during the recovery stage, whereas
overexpression of the strong individual growth factor such as PlGF, can affect anaerobic
metabolism during the exercise. These results are important, as in PAD patients have been
reported to experince problems in restoring PCr levels after exercise. (Greiner et al., 2006) Since
HIFs were able to accelerate the recovery of the ischemic skeletal muscle, this may represent a
new therapeutic approach for improving muscle function of PAD patients. Further studies are
important in determining the contribution of direct effects of HIFs on metabolism apart from
those mediated by increased blood flow.
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7 Conclusions
I The expression profile of PDGF-C and PDGF-D and their receptors in normal
human arteries and in atherosclerotic lesions was characterized. Novel PDGF
family members have different expression profiles in lesions and both of these
factors are clearly present in normal arteries indicating that they are likely to be
involved in vascular homeostasis.
II Adenoviral PDGF-B gene transfer induced moderate angiogenesis but the effects
remained for up to 28 days.  Combining PFGF-B with VEGF-A gene transfer did
not improve vessel maturation. On the contrary, PDGF-B caused pericyte
detachment, probably due to an improper PDGF-B gradient.
III AAV-VEGF-A is a powerful angiogenic factor and that can promote angiogene
sis in the rabbit skeletal muscle. However, long-lasting expression of VEGF-A
appears to evoke local unfavorable effects which will need to be considered
when  designing future therapeutic applications.
IV Adenoviral overexpression of HIF-1α HIF-2α induces angiogenesis in both rabbit
normoperfused and ischemic skeletal muscles. Additionally, gene transfer of
AdHIF-1α and -2α elevates skeletal muscle energy metabolism via improving
blood flow and the oxygen supply to the ischemic area.
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New treatment strategies for the 
patient suffering from cardiovascular 
diseases are needed. Gene therapy 
may offer a novel opportunity to 
improve vascular growth in ischemic 
tissue. In this thesis, growth factor 
expression in human atherosclerotic 
arteries was described. In addition, 
gene transfer into ischemic limb was 
observed to increase angiogenesis 
and improve the recovery of skeletal 
muscle from the energy deprivation 
induced by exercise.
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